Stericycle

A N N U A L

R E P O R T

2 0 0 7

Dear Fellow Shareholders:

In 2007 Stericycle continued to set new Company financial
records, to expand our range of service offerings in the U.S.
and to grow internationally.

Revenues in 2007 grew to $932.8 million, an 18.1% increase
over 2006. Gross margins were 44.8% versus 44.3% in 2006.
Operating income rose 11.3% to $224.5 million from $201.8
million in 2006. Operating margins were 24.1% versus 25.6%
in 2006.

Under generally accepted accounting principles (“GAAP”), net
income for 2007 increased 12.5% from $105.3 million to $118.4
million and diluted earnings per share increased 13.2% from $1.16
to $1.32 per diluted share. This result reflects the following one-time
events that had a combined effect of reducing our net income by
$9.3 million or $0.10 per diluted share: a partially adverse award
in arbitration proceedings in Australia, the write-down of a joint
venture investment in Argentina, and the write-down of impaired
intangibles and impaired fixed assets, which events were partially
offset by the receipt of insurance proceeds related to the 2005 3CI
class action litigation settlement and by the gain recognized on the
divestiture of selected business operations in the United Kingdom.
Excluding the impact of these items on our results in both 2006
and 2007, our non-GAAP net income in 2007 increased 21.1%
over our non-GAAP net income in 2006.

Accomplishments In 2007

We continued to generate strong free cash flow from operations,
which we used to fund growth and improve our balance sheet.
During 2007, we invested $48.4 million of the $174.0 million in
cash generated from operations in our infrastructure. We expanded
our service offerings and processing network and supported the
growth of Bio Systems®, our innovative sharps management
solution that reduces the risk of inadvertent needle sticks, and of
our returns management services, our comprehensive outsourced
solution for returns and recall management. In addition, we used
$114.8 million for acquisitions. Finally, we repurchased $103.7
million in stock on the open market.

Domestically: We continued to strengthen Stericycle’s leadership
position in regulated waste management and healthcare safety and
compliance services. We successfully increased the penetration of
Steri•SafeSM, our OSHA safety and compliance solution, helping
even more healthcare providers throughout the United States create
a safer, more compliant workplace. We continued to achieve strong
customer adoption of our integrated sharps management solution.
We achieved strong growth of our returns management services
business fueled by new account growth and an increase in recall
events. In 2007, we integrated 11 acquisitions of regulated waste
businesses into our existing collection route, transfer station and
processing plant infrastructure.

Internationally: We started the integration of Sterile Technologies
Group, Ltd. with our other operations in the United Kingdom after
completing the sale of overlapping assets. We strengthened our
businesses in Mexico, Argentina and Canada both organically and
by integrating acquisitions.

Priorities for 2008

By building on Stericycle’s industry leadership position in 2007,
we are confident that we have the operating platform that we
need to drive future growth and explore opportunities to serve
our customers better. Our priorities for 2008 are:

Domestic Growth: Our focus will be on our Steri•SafeSM,
Bio Systems and return management service offerings. Our
marketing efforts to small quantity generators will concentrate
on our Steri•SafeSM OSHA safety and compliance services and
regulated waste management services. Our marketing focus
for large quantity generators will be on extending the momentum
of the Bio Systems® sharps management solution and expanding
the return management services. We will focus overall on creating
best-in-class customer service and meeting customer needs with
additional service offerings.

International Growth: We will remain focused on integrating
the acquisitions completed and on pursuing attractive international
market opportunities directed to providing value to our shareholders
over the course of the next several years.

Profit Growth: We are committed to extending our track record
of improving our operating margins. We will seek to make further
improvements to our collection route densities, reduce our long-
haul transportation costs and improve efficiency in our processing
plants. Our culture of continuous improvement encourages the
sharing of best practices and productivity improvement ideas
across our entire organization.

Service Innovation and Environmental Leadership: Service
Innovation and Environmental Leadership: During 2008, we will
maintain our twin commitments to being responsive to our customers’
needs and an environmental leader by offering services suited to the
needs of our customers. Our innovative Steri•SafeSM OSHA safety
and compliance services will continue to help our customers to enjoy
a safer, more compliant workplace in a cost-effective manner. Our
return management offerings can help our customers reduce liability.
Our other innovative outsourcing programs, such as our Bio Systems®
sharps management service featuring reusable containers, offer
significant environmental benefits by reducing waste volume and
conserving valuable natural resources.

• • •
We are excited and confident about our future. Through our many
service offerings, we help our customers protect the safety of their
workforce and reduce risk. We are a clear leader in providing regulated
waste management, safety compliance, sharps management and
return management services. We will focus on the many growth
opportunities that our leadership position affords us. We will continue
to refine the efficiency of our operations and improve our customers’
experience while maintaining our strong focus on safety and
regulatory compliance. We thank you for your support.

Jack W. Schuler
Chairman

Mark C. Miller
President and CEO

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2007

or

‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934
For the transition period from

to

Commission File Number 0-21229

Stericycle, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

36-3640402
(IRS Employer
Identification Number)

28161 North Keith Drive
Lake Forest, Illinois 60045
(Address of principal executive offices including zip code)

(847) 367-5910
(Registrant’s telephone number, including area code)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities

Act. Yes È No ‘

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities

Act of 1934. Yes ‘ No È

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required
to file reports), and (2) has been subject to such filing requirements for the past 90 days. Yes È No ‘

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this
chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K, or any amendment to this Form 10-K. È

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

See the definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one)
Large accelerated filer È Accelerated filer ‘ Non-accelerated filer ‘

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the

Exchange Act). Yes ‘ No È

The aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to
the price at which common equity was last sold as of the last business day of the registrant’s most recently completed second
fiscal quarter (June 30, 2007) was: $3,891,770.

On February 21, 2008, there were 87,484,623 shares of the Registrant’s Common Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Information required by Items 10, 11, 12 and 13 of Part III of this Report is incorporated by reference from the

Registrant’s definitive Proxy Statement for the 2008 Annual Meeting of Stockholders to be held on May 29, 2008.

Stericycle, Inc.

2007 ANNUAL REPORT ON FORM 10-K

TABLE OF CONTENTS

Page No.

Part I.

Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.

Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Submission of Matters to a Vote of Security Holders . . . . . . . . . . . . . . . . . . . . . . . . . .

Part II.

Item 5.

Market Price of and Dividends on the Registrant’s Common Equity and Related

Item 6.
Item 7.

Item 7A.
Item 8.
Item 9.

Item 9A.
Item 9B.

Stockholder Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selected Consolidated Financial Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Management’s Discussion and Analysis of Financial Condition and Results of

Operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Quantitative and Qualitative Disclosures about Market Risk . . . . . . . . . . . . . . . . . . . .
Consolidated Financial Statements and Supplemental Data . . . . . . . . . . . . . . . . . . . . .
Changes in and Disagreements with Accountants on Accounting and Financial

Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Part III.

Item 10.
Item 11.
Item 12.

Item 13.
Item 14.

Directors and Executive Officers of the Registrant . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Security Ownership of Certain Beneficial Owners and Management and Related

Stockholder Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Certain Relationships and Related Transactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Principal Accountant Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Part IV.

Item 15.

Exhibits and Financial Statement Schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Signature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1
9
12
12
12
13

15
18

19
27
28

57
57
57

58
58

58
58
58

60

63

Item 1. Business

PART I.

Unless the context requires otherwise, “we,” “us” or “our” refers to Stericycle, Inc. and its subsidiaries on a

consolidated basis.

Overview

We are in the business of managing regulated waste and providing an array of related services. We operate

in the United States, Canada, Mexico, the United Kingdom, Ireland and Argentina.

For large-quantity generators of regulated waste such as hospitals and for pharmaceutical companies and

distributors, we offer:

•

•

•

•

our institutional regulated waste management services

our Bio Systems® sharps management services to reduce the risk of needle sticks

a variety of products and services for infection control

our regulated returns management services for expired or recalled healthcare products

For small-quantity generators of regulated waste such as doctors’ offices and for retail pharmacies, we offer:

•

•

•

•

our regulated waste management services

our Steri-Safe® Occupational Safety and Health Act and Health Insurance Portability and
Accountability Act (“HIPAA”) compliance programs

a variety of products and services for infection control

our regulated returns management services for expired or recalled healthcare products

We operate integrated national regulated waste management networks in the United States, Canada, Mexico,
Argentina, the United Kingdom and Ireland. Our national networks include a total of 78 processing or combined
processing and collection sites and 98 additional transfer, collection or combined transfer and collection sites.

Our

regulated waste processing technologies include autoclaving, our proprietary electro-thermal-

deactivation system (“ETD”), chemical treatment and incineration.

We serve approximately 394,600 customers worldwide, of which approximately 9,700 are large-quantity
generators, such as hospitals, blood banks and pharmaceutical manufacturers, and approximately 384,900 are
small-quantity generators, such as outpatient clinics, medical and dental offices, long-term and sub-acute care
facilities and retail pharmacies.

We benefit from significant customer diversification. No one customer accounts for more than 2% of our

total revenues, and our top 10 customers account for approximately 8% of total revenues.

Industry Overview

Governmental legislation and regulation increasingly requires the proper handling and disposal of regulated
waste. Regulated medical waste is generally any medical waste that can cause an infectious disease and includes:
single-use disposable items, such as needles, syringes, gloves and other medical supplies; cultures and stocks of
infectious agents; and blood and blood products. Regulated pharmaceutical waste consists of expired or recalled
pharmaceuticals.

1

During 2007, we believe the size of the global regulated waste market for the services we provide was
approximately $10.0 billion. We estimate that our global market share increased to 9.3% in 2007 from 7.9% in
2006. Industry growth is driven by a number of factors. These factors include:

• Aging of Population: The average age of the population in the countries we operate in is rising. As
people age, they typically require more medical attention and a wider variety of tests, procedures and
medications, leading to an increase in the quantity of regulated waste generated.

• Pressure to Reduce Healthcare Costs: The healthcare industry is under pressure to reduce costs. We
believe that our services can help healthcare providers to reduce their handling and compliance costs
and to reduce their potential liability for employee exposure to blood-borne pathogens and other
infectious agents.

• Environmental and Safety Regulation: We believe that many businesses that are not currently using
third party regulated waste services are unaware either of the need for proper training of employees or
of the requirements of the Occupational Safety and Health Administration (“OSHA”) regarding the
handling of regulated waste. These businesses include manufacturing facilities, schools, restaurants,
hotels and other businesses where employees may come into contact with blood-borne pathogens.
Similarly, the proper handling of expired or recalled pharmaceuticals requires an expertise that many
retail pharmacies lack or find inefficient to provide.

•

Shift to Off-Site Treatment: We believe that patient care is continuing to shift from institutional
higher-cost acute-care settings to less expensive, smaller, off-site treatment alternatives, with a
resulting increase in the number of regulated waste generators that cannot treat their own regulated
waste.

• Control of Drug Diversion: The U.S. Drug Enforcement Administration (“DEA”) has recently
emphasized improved control of the handling and shipment of controlled substances to prevent
diversion and counterfeiting,
thus increasing the utility to pharmaceutical manufacturers and
distributors of a returns service for expired or recalled pharmaceuticals.

Competitive Strengths

We believe that we benefit from the following competitive strengths, among others:

• Broad Range of Services: We offer our customers a broad range of services to help them develop
systems and processes to manage their regulated waste safely and efficiently. For example, we have
developed programs to help our customers ensure and maintain compliance with OSHA and HIPAA
regulations.

• Established National Network: We believe that a network like ours would be very expensive and time-

consuming for a competitor to develop.

• Diverse Customer Base and Revenue Stability: We have a very diverse customer base in all the
markets in which we operate. We are also generally protected from the cost of regulatory changes and
increases in fuel, insurance and other operating costs because our regulated waste contracts typically
allow us to adjust our prices to reflect these cost increases.

•

Strong Sales Network and Proprietary Database: We use both telemarketing and direct sales efforts to
obtain new regulated waste customers. In addition, we have a large database of potential new small-
quantity customers, which we believe gives us a competitive advantage in identifying and reaching this
higher-margin sector.

• Experienced Senior Management Team: We have experienced leadership. Our six most senior
executives collectively have over 150 years of management experience in the health care, consumer
and waste management industries.

• Ability to Integrate Acquisitions: We have completed 135 acquisitions since 1993 and have

demonstrated a consistent ability to integrate our acquisitions into our operations successfully.

2

Our goals are to strengthen our position as a leading provider of regulated waste and compliance services

and to continue to improve our profitability. Components of our strategy to achieve these goals include:

• Expand Range of Services and Products: We believe that we continue to have opportunities to expand
our business by increasing the range of products and services that we offer our existing regulated waste
customers. For example, through our Steri-Safe® program, we now offer OSHA compliance services to
small-quantity customers, and an acquisition in 2003 enabled us to market the Bio Systems® sharps
management program to large-quantity customers in new geographic areas. We have expanded our
regulated waste services to pharmaceutical companies and other large-quantity generators through a
series of acquisitions in 2005 and 2006 of five businesses engaged in regulated returns and recall
management services.

•

•

Improve Margins: We intend to continue working to improve our margins by increasing our base of
small-quantity customers and focusing on service strategies that more efficiently meet the needs of our
large-quantity customers. We have succeeded in raising the percentage of our revenues from small-
quantity customers from 33% of domestic medical waste revenues at the fourth quarter of 1996 to 63%
for the year ended 2007.

Seek Complementary Acquisitions: We intend to continue to seek opportunities to acquire businesses
that expand our national networks in the United States and internationally and increase our customer
base. We believe that selective acquisitions can enable us to improve our operating efficiencies through
increased utilization of our service infrastructure.

Acquisitions

We have substantial experience in evaluating potential acquisitions and determining whether a particular
waste business can be integrated into our operations with minimal disruption. Once a business is acquired, we
implement programs and procedures to improve customer service, sales, marketing, routing, equipment
utilization, employee productivity, operating efficiency and overall profitability.

We completed 135 acquisitions from 1993 through 2007, with 100 in the United States and 35

internationally.

During 2007, we completed 19 acquisitions, of which ten were domestic medical waste businesses, one was
a domestic assembler and distributor of containers that we use in our mail-back program, one was a medical
waste business in Canada, six were medical waste businesses in Latin America, and one was a medical waste
business in Europe. In addition, we acquired the minority interest of our Medam S.A. de C.V. subsidiary in
Mexico and became the sole owner of our Medam B.A. subsidiary in Argentina, previously accounted for as a
minority interest using the equity method of accounting.

Services and Operations

Collection and Transportation: In many respects, our regulated waste business is one of logistics.
Efficiency of collection and transportation of regulated waste is a critical element of our operations because it
represents the largest component of our operating costs.

For regulated waste, we supply specially designed reusable leak-and puncture-resistant plastic containers to
most of our large-quantity customers and many of our larger small-quantity customers. To assure regulatory
compliance, we will not accept regulated waste from customers unless it is properly packaged in containers that
we have either supplied or approved.

We collect containers or corrugated boxes of regulated waste from our customers at intervals depending
upon customer requirements, contract terms and volume of waste generated. The waste is then transported
directly to one of our processing facilities or to one of our transfer stations where it is combined with other
regulated waste and transported to a processing facility.

3

Transfer stations allow us to temporarily hold small loads of waste until they can be consolidated into full
truckloads and transported to a processing facility. Our use of transfer stations in a “hub and spoke”
configuration improves the efficiency of our collection and transportation operations by expanding the
geographic area that a particular processing facility can serve and thereby increasing utilization of the facility by
increasing the volume of waste that it processes.

We collect some expired or recalled pharmaceuticals from pharmacy shelves, but more typically,

pharmacies ship them directly to our processing facilities.

Processing and Disposal: Upon arrival at a processing facility, containers or boxes of regulated waste are
typically scanned to verify that they do not contain any unacceptable substances like radioactive material. Any
container or box that is discovered to contain unacceptable waste is returned to the customer and the appropriate
regulatory authorities are informed.

The regulated waste is then processed using one of our various treatment technologies. Upon completion of
the particular process, the resulting waste or incinerator ash is transported for resource recovery, recycling or
disposal in a landfill operated by an unaffiliated third party. We do not own any landfills. After plastic containers
such as our Steri-Tub® or Bio Systems® containers have been emptied, they are washed, sanitized and returned to
customers for re-use.

Upon receipt at a processing facility, expired or recalled pharmaceuticals are counted and logged, and
controlled substances are stored securely. In accordance with the manufacturer’s instructions, expired or recalled
pharmaceuticals are then returned to the manufacturer or destroyed in compliance with applicable regulations.

Documentation: We provide complete documentation to our customers for all regulated waste that we

collect in accordance with applicable regulations and customer requirements.

Marketing and Sales

Marketing Strategy: We use both telemarketing and direct sales efforts to obtain new customers. In
addition, our drivers may also participate in our regulated waste marketing efforts by actively soliciting small-
quantity customers they service.

Small-Quantity Customers: We target small-quantity customers as a growth area of our regulated waste
business. We believe that small-quantity regulated waste customers view the potential risks of failing to comply
with applicable state and federal regulated waste regulations as disproportionate to the cost of the services that
we provide. We believe that this factor has been the basis for the significantly higher gross margins that we have
achieved with our small-quantity customers relative to our large-quantity customers. We believe that the same
potential exists in processing returns of expired pharmaceuticals for smaller retail pharmacies.

Steri-Safe®: Our Steri-Safe® OSHA compliance program provides an integrated regulated waste
management and compliance-assistance service for small-quantity customers who typically lack the internal
personnel and systems to comply with OSHA blood-borne regulations. Customers for our Steri-Safe® service pay
a predetermined subscription fee in advance for regulated waste collection and processing services and can also
choose from available packages of training and education services and products designed to help them to comply
with OSHA regulations. Approximately 117,000 small-quantity customers are enrolled in this program. We
believe that the implementation of our Steri-Safe® service provides us with an enhanced opportunity to leverage
our existing customer base through the program’s prepayment structure and diversified product and service
offerings.

Mail-Back Program: We also operate a “mail-back” program by which we can reach small-quantity
regulated waste customers located in outlying areas that would be inefficient to serve using our regular route
structure. Our mail-back program has allowed us to service customers as far away as Hawaii, Guam and the
Virgin Islands. Mail-back programs are also used in home care patient settings.

4

Large-Quantity Customers: Our marketing efforts to large-quantity customers are conducted by account
executives that are also able to provide consulting services to assist our large-quantity customers in training their
employees on safety issues and implementing programs to improve waste segregation.

Our Bio Systems® sharps management offering can enhance our revenue and margins per large-quantity
account. The Bio Systems® service can help our large-quantity customers eliminate plastic and cardboard from
their waste stream while providing a safe and cost-effective way for them to deal with the disposal of their sharp
objects (such as needles, syringes, etc.).

We offer hospital pharmacies an onsite collection service to assist them in accounting for and segregating

expired or recalled pharmaceuticals.

National Accounts: As a result of our extensive geographic coverage, we are capable of servicing national
account customers (i.e., customers requiring regulated waste services at various geographically dispersed
locations).

Contracts: We have multi-year contracts with a large majority of our customers. We negotiate individual
contracts with each large-quantity and small-quantity customer. Although we have a standard form of contract,
particularly for small-quantity customers, terms may vary depending upon the customer’s service requirements
and the volume of regulated waste generated and, in some jurisdictions, statutory and regulatory requirements.
Substantially all of our contracts with small-quantity customers contain automatic renewal provisions.

International

We conduct regulated waste operations in Canada, Mexico, Argentina, the United Kingdom and Ireland. We
began our operations in Canada and Mexico in 1998, in Argentina in 1999, in the United Kingdom in 2004 and in
Ireland in 2006. We also have technology licensing agreements in Japan, Brazil and South Africa.

Processing Technologies

We currently use both non-incineration technologies (autoclaving, chemical treatment and our proprietary

ETD technology) and incineration technologies for treating regulated waste.

Stericycle was founded on the belief that there was a need for safe, secure and environmentally responsible
management of regulated waste. From our beginning we have championed the use of non-incineration treatment
technologies such as our ETD process. While we recognize that some state regulations currently in force mandate
that some types of regulated waste must be incinerated, we also know from years of experience working with our
customers that there are ways to reduce the amount of regulated waste that is ultimately incinerated. The most
effective strategy that we have seen involves comprehensive education of our customers in waste minimization
and segregation. Working in cooperation with our customers, we have made tremendous strides in moving away
from incineration and towards alternate treatment technologies. At the end of 2007, incineration constituted
approximately 9% of our treatment capacity in North America.

Autoclaving: Autoclaving treats regulated waste with steam at high temperature and pressure to kill
pathogens. Autoclaving alone does not change the appearance of waste, and some landfill operators may not
accept recognizable regulated waste, but autoclaving may be combined with a shredding or grinding process to
render the regulated waste unrecognizable.

ETD: Our ETD treatment process includes a system for grinding regulated waste. After grinding, ETD uses
an oscillating field of low-frequency radio waves to heat regulated waste to temperatures that destroy pathogens
such as viruses, bacteria, fungi and yeast without melting the plastic content of the waste. ETD does not produce
regulated air or water emissions.

5

Incineration: Incineration burns regulated waste at elevated temperatures and reduces it to ash. Incineration
reduces the volume of waste, and it is the recommended treatment and disposal option for some types of
regulated waste such as anatomical waste or residues from chemotherapy procedures. Air emissions from
incinerators can contain certain byproducts that are subject to federal, state and, in some cases, local regulation.
In some circumstances, the ash byproduct of incineration may be regulated.

Chem-Clav: Chemclaving treats regulated waste using high heat, pressure, and a steam auger to kill
pathogens. The waste is treated in a sealed container while the auger shreds the waste, making it unrecognizable
while exposing more surface area of the waste to the steam. After shredding and treatment, the waste residue is
sterile and safe for landfill.

Competition

The regulated waste industry is highly competitive, and barriers to entry into the regulated waste collection
and disposal business and the pharmaceutical returns business are very low. Our competitors consist of many
different types of service providers, including a large number of regional and local companies. In the regulated
waste industry, another major source of competition is the on-site treatment of regulated waste by some large-
quantity generators, particularly hospitals.

In addition,

in the regulated waste industry we face potential competition from businesses that are
attempting to commercialize alternate treatment technologies or products designed to reduce or eliminate the
generation of regulated waste, such as reusable or degradable medical products.

Governmental Regulation

The regulated waste industry is subject to extensive and frequently changing federal, state and local laws
and regulations. This statutory and regulatory framework imposes a variety of compliance requirements,
including requirements to obtain and maintain government permits. These permits grant us the authority, among
other things:

•

•

•

to construct and operate collection, transfer and processing facilities,

to transport regulated waste within and between relevant jurisdictions, and

to handle particular regulated substances.

Our permits must be periodically renewed and are subject to modification or revocation by the issuing

authority.

We are also subject to regulations that govern the definition, generation, segregation, handling, packaging,
transportation, treatment, storage and disposal of regulated waste. We are also subject to extensive regulations
designed to minimize employee exposure to regulated waste.

Domestic Federal Regulation: Five federal agencies have authority over regulated waste. These agencies
are the U.S. Environmental Protection Agency (“EPA”), OSHA, U.S. Department of Transportation (“DOT”),
the U.S. Postal Service (“USPS”) and DEA. These agencies supervise regulated waste under a variety of statutes
and regulations. The principal statutes and regulations are:

• Medical Tracking Act of 1988. In the late 1980s, the EPA outlined a two-year demonstration program
pursuant
to the Medical Waste Tracking Act (“MWTA”), which was added to the Resource
Conservation and Recovery Act of 1976. In regulations implementing the MWTA, the EPA defined
medical waste and established guidelines for its segregation, handling, containment, labeling and
transport. The MWTA demonstration program expired in 1991, but the MWTA established a model
followed by many states in developing their specific medical waste regulatory framework.

6

• Occupational Safety and Health Act of 1970. The Occupational Safety and Health Act of 1970
authorizes OSHA to issue occupational safety and health standards. Various standards apply to certain
aspects of our operations and govern such matters as exposure to blood borne pathogens and other
potentially infectious materials.

• Resource Conservation and Recovery Act of 1976. The Resource Conservation and Recovery Act of
1976 (“RCRA”) created standards for the generation, transportation, treatment, storage and disposal of
solid and hazardous wastes. Medical wastes are currently considered non-hazardous solid wastes under
including
RCRA. However, some substances collected by us from some of our customers,
photographic fixer developer solutions, lead foils and dental amalgam, are considered hazardous
wastes.

• Clean Air Act Regulations. In August 1997, the EPA adopted regulations under the Clean Air Act
Amendments of 1990 that limit the discharge into the atmosphere of pollutants released by regulated
waste incineration. These regulations required every state to submit to the EPA for approval a plan to
meet minimum emission standards for these pollutants. We currently operate seven incinerators in the
United States. We believe these incinerators are in compliance with applicable state requirements.

• DOT Regulations. DOT has adopted regulations under the Hazardous Materials Transportation
Authorization Act of 1994 that require us to package and label regulated waste in compliance with
designated standards, and which incorporate blood borne pathogens standards issued by OSHA. Under
these standards, we must, among other things, identify our packaging with a “biohazard” marking on
the outer packaging, and our regulated waste container must be sufficiently rigid and strong to prevent
tearing or bursting. It must also be puncture-resistant, leak-resistant, properly sealed and impervious to
moisture.

Expired or recalled pharmaceuticals are subject to the substantially same DOT regulations as medical
waste. We identify these products by their National Drug Code number and classify them by their
handling, transportation and disposal requirements.

• Comprehensive Environmental Response, Compensation and Liability Act of 1980. The Comprehensive
Environmental Response, Compensation and Liability Act of 1980 (“CERCLA”) established a
regulatory and remedial program to provide for the investigation and cleanup of facilities that have
released or threaten to release hazardous substances into the environment. CERCLA and state laws
similar to it may impose strict, joint and several liability on the current and former owners and
operators of facilities from which releases of hazardous substances have occurred and on the generators
and transporters of the hazardous substances that come to be located at these facilities.

• USPS Regulations. We have obtained permits from the USPS to conduct our “mail-back” program,
pursuant to which customers mail approved containers of “sharps” (needles, knives, broken glass and
the like) directly to our treatment facilities.

• Controlled Substances Act. Our returns service for expired and recalled pharmaceuticals is required to
comply with DEA regulations relating to the approval and permitting of processing facilities,
management of employees engaged in the collection, processing and disposal of controlled substances,
proper documentation and reporting to the DEA.

We use landfills owned and operated by unrelated third parties for the disposal of waste from our processing

facilities.

Domestic State and Local Regulation: We conduct business in all 50 states and Puerto Rico. Each state has
its own regulations related to the handling, treatment and storage of regulated waste. Although there are many
differences among the various state laws and regulations, for regulated waste many states have followed the
model under the MWTA and have implemented programs under RCRA. In each state where we operate a
processing facility or a transfer station, we are required to comply with numerous state and local laws and
regulations as well as our operating plan for each site. In addition, many local governments have ordinances and
regulations, such as zoning and health regulations that affect our operations.

7

We maintain numerous governmental permits and licenses to conduct our business. Our permits vary from
state to state based upon our activities within that state and on the applicable state and local laws and regulations.

Foreign Regulation: We are subject

to substantial regulation by the governments of the foreign
jurisdictions in which we conduct regulated waste operations. The statutory and regulatory requirements vary
from jurisdiction to jurisdiction.

Patents and Proprietary Rights

We consider the protection of our technology to be important to our business. Our policy is to protect our
technology by a variety of means, including applying for patents in the United States and in other foreign
countries.

We hold 7 current United States patents relating to the ETD treatment process and other aspects of
processing regulated waste. We have filed or have been assigned patent applications in several foreign countries
and we have received patents in Australia, Canada, Denmark, France, Ireland, Italy, Japan, Mexico, South Africa,
South Korea, Spain, Sweden and the United Kingdom.

The term of the first-to-end of our existing United States patents relating to our ETD treatment process will

currently end in May 2009 and the term of the last-to-end will currently end in January 2019.

We own federal registrations of the trademarks “Steri-Fuel®”, “Steri-Plastic®”, “Steri-Tub®”, “Direct

Return®”, “Steri-Safe®”, the service mark Stericycle® and a service mark consisting of a nine-circle design.

Potential Liability and Insurance

The regulated waste industry involves potentially significant risks of statutory, contractual, tort and common

law liability claims. Potential liability claims could involve, for example:

•

•

•

•

•

•

cleanup costs;

personal injury;

damage to the environment;

employee matters;

property damage; or

alleged negligence or professional errors or omissions in the planning or performance of work.

We could also be subject to fines or penalties in connection with violations of regulatory requirements.

We carry $35 million of liability insurance (including umbrella coverage), and under a separate policy, $10
million of aggregate pollution and legal liability insurance ($5 million per incident), which we consider sufficient
to meet regulatory and customer requirements and to protect our employees, assets and operations.

Employees

As of December 31, 2007, we had 6,090 full-time and 252 part-time employees, of which 4,569 were
employed in the United States and 1,773 internationally. Approximately 355 of our U.S. drivers, transportation
helpers and plant workers are covered by a total of seven collective bargaining agreements with local unions of
the International Brotherhood of Teamsters. These agreements expire at various dates from April 2007 to
November 2010. We consider our employee relations to be satisfactory.

8

Website Access

We maintain an Internet website, www.stericycle.com, providing a variety of information about us. Our
annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to
those reports, that we file with the Securities and Exchange Commission are available, as soon as reasonably
practicable after filing, at the investors’ page on our website, or by a direct link to our filings on the SEC’s free
website, www.sec.gov.

Item 1A. Risk Factors

We are subject to extensive governmental regulation, which is frequently difficult, expensive and time-
consuming to comply with.

industry is subject

The regulated waste management

to extensive federal, state and local

laws and
regulations relating to the collection, transportation, packaging, labeling, handling, documentation, reporting,
treatment and disposal of regulated waste. Our business requires us to obtain many permits, authorizations,
approvals, certificates or other types of governmental permission from every jurisdiction where we operate. We
believe that we currently comply in all material respects with all applicable permitting requirements. State and
local regulations change often, however, and new regulations are frequently adopted. Changes in the regulations
could require us to obtain new permits or to change the way in which we operate under existing permits. We
might be unable to obtain the new permits that we require, and the cost of compliance with new or changed
regulations could be significant.

Many of the permits that we require, especially those to build and operate processing plants and transfer
facilities, are difficult and time-consuming to obtain. They may also contain conditions or restrictions that limit
our ability to operate efficiently, and they may not be issued as quickly as we need them (or at all). If we cannot
obtain the permits that we need when we need them, or if they contain unfavorable conditions, it could
substantially impair our operations and reduce our revenues.

The handling and treatment of regulated waste carries with it the risk of personal injury to employees and
others.

Our business requires us to handle materials that may be infectious or hazardous to life and property in other
ways. While we try to handle such materials with care and in accordance with accepted and safe methods, the
possibility of accidents, leaks, spills, and acts of God always exists. Examples of possible exposure to such
materials include:

•

•

•

•

truck accidents;

damaged or leaking containers;

improper storage of regulated waste by customers;

improper placement by customers of materials into the waste stream that we are not authorized or able
to process, such as certain body parts and tissues; or

• malfunctioning treatment plant equipment.

Human beings, animals or property could be injured, sickened or damaged by exposure to regulated waste.
This in turn could result in lawsuits in which we are found liable for such injuries, and substantial damages could
be awarded against us.

While we carry liability insurance intended to cover these contingencies, particular instances may occur that
are not insured against or that are inadequately insured against. An uninsured or underinsured loss could be
substantial and could impair our profitability and reduce our liquidity.

9

The handling of regulated waste exposes us to the risk of environmental liabilities, which may not be covered
by insurance.

As a company engaged in regulated waste management, we face risks of liability for environmental
contamination. The federal Comprehensive Environmental Response, Compensation and Liability Act of 1980,
or CERCLA, and similar state laws impose strict liability on current or former owners and operators of facilities
that release hazardous substances into the environment as well as on the businesses that generate those
substances and the businesses that transport them to the facilities. Responsible parties may be liable for
substantial investigation and clean-up costs even if they operated their businesses properly and complied with
applicable federal and state laws and regulations. Liability under CERCLA may be joint and several, which
means that if we were found to be a business with responsibility for a particular CERCLA site, we could be
required to pay the entire cost of the investigation and clean-up even though we were not the party responsible
for the release of the hazardous substance and even though other companies might also be liable.

Our pollution liability insurance excludes liabilities under CERCLA. Thus, if we were to incur liability
under CERCLA and if we could not identify other parties responsible under the law whom we are able to compel
to contribute to our expenses, the cost to us could be substantial and could impair our profitability and reduce our
liquidity. Our customer service agreements make clear that the customer is responsible for making sure that only
appropriate materials are disposed of. If there were a claim against us that a customer might be legally liable for,
we might not be successful in recovering our damages from the customer.

The level of governmental enforcement of environmental regulations has an uncertain effect on our business
and could reduce the demand for our services.

We believe that the government’s strict enforcement of laws and regulations relating to regulated waste
collection and treatment has been good for our business. These laws and regulations increase the demand for our
services. A relaxation of standards or other changes in governmental regulation of regulated waste could increase
the number of competitors or reduce the need for our services.

If we are unable to acquire other regulated waste businesses, our revenue and profit growth may be slowed.

Historically our growth strategy has been based in substantial part on our ability to acquire other regulated

waste businesses. We do not know whether in the future we will be able to:

•

•

•

•

identify suitable businesses to buy;

complete the purchase of those businesses on terms acceptable to us;

improve the operations of the businesses that we do buy and successfully integrate their operations into
our own; or

avoid or overcome any concerns expressed by regulators.

We compete with other potential buyers for the acquisition of other regulated waste companies. This
competition may result in fewer opportunities to purchase companies that are for sale. It may also result in higher
purchase prices for the businesses that we want to purchase.

We also do not know whether our growth strategy will continue to be effective. Our business is significantly

larger than before, and new acquisitions may not have the desired benefits that we have obtained in the past.

The implementation of our acquisition strategy could be affected in certain instances by the concerns of state
regulators, which could result in our not being able to realize the full synergies or profitability of particular
acquisitions.

We may become subject to inquiries and investigations by state antitrust regulators from time to time in the
course of completing acquisitions of other regulated waste businesses. In order to obtain regulatory clearance for

10

a particular acquisition, we could be required to modify certain operating practices of the acquired business or to
divest ourselves of one or more assets of the acquired business. Changes in the terms of our acquisitions required
by regulators or agreed to by us in order to settle regulatory investigations could impede our acquisition strategy
or reduce the anticipated synergies or profitability of our acquisitions. The likelihood and outcome of inquiries
and investigations from state regulators in the course of completing acquisitions cannot be predicted.

Aggressive pricing by existing competitors and the entrance of new competitors could drive down our profits
and slow our growth.

The regulated waste industry is very competitive because of low barriers to entry, among other reasons. This
competition has required us in the past to reduce our prices, especially to large account customers, and may
require us to reduce our prices in the future. Substantial price reductions could significantly reduce our earnings.

We face direct competition from a large number of small, local competitors. Because it requires very little
money or technical know-how to compete with us in the collection and transportation of regulated waste, there
are many regional and local companies in the industry. We face competition from these businesses, and
competition from them is likely to exist in the new locations to which we may expand in the future. In addition,
large national companies with substantial resources may decide to enter the regulated waste industry. For
example, Waste Management, Inc., a major solid waste treatment company, announced in February 2005 that it
intended to begin offering regulated waste management services to hospitals and possibly other large quantity
generators of regulated waste.

Our competitors could take actions that would hurt our growth strategy, including the support of regulations
that could delay or prevent us from obtaining or keeping permits. They might also give financial support to
citizens’ groups that oppose our plans to locate a treatment or transfer facility at a particular location.

Restrictions in our senior unsecured credit facility may limit our ability to pay dividends, incur additional debt,
make acquisitions and make other investments.

Our senior unsecured credit facility contains covenants that restrict our ability to make distributions to

stockholders or other payments unless we satisfy certain financial tests and comply with various financial ratios.

It also contains covenants that limit our ability to incur additional indebtedness, acquire other businesses and
make capital expenditures, and imposes various other restrictions. These covenants could affect our ability to
operate our business and may limit our ability to take advantage of potential business opportunities as they arise.

The loss of our senior executives could affect our ability to manage our business profitably.

We depend on a small number of senior executives. Our future success will depend upon, among other things,
our ability to keep these executives and to hire other highly qualified employees at all levels. We compete with other
potential employers for employees, and we may not be successful in hiring and keeping the executives and other
employees that we need. We do not have written employment agreements with any of our executive officers, and
officers and other key employees could leave us with little or no prior notice, either individually or as part of a group.
Our loss of or inability to hire key employees could impair our ability to manage our business and direct its growth.

Our expansion into foreign countries exposes us to unfamiliar regulations and may expose us to new obstacles
to growth.

We plan to grow both in the United States and in foreign countries. We have established operations in
Argentina, Canada, Ireland, Mexico and the United Kingdom. Foreign operations carry special risks. Although
our business in foreign countries has not yet been affected, our business in the countries in which we currently
operate and those in which we may operate in the future could be limited or disrupted by:

•

•

government controls;

import and export license requirements;

11

•

•

•

•

•

•

•

political or economic instability;

trade restrictions;

changes in tariffs and taxes;

exchange rate fluctuations;

our unfamiliarity with local laws, regulations, practices and customs;

restrictions on repatriating foreign profits back to the United States;

difficulties in staffing and managing international operations.

Foreign governments and agencies often establish permit and regulatory standards different from those in
the United States. If we cannot obtain foreign regulatory approvals, or if we cannot obtain them when we expect,
our growth and profitability from international operations could be limited. Fluctuations in currency exchange
could have similar effects.

Our earnings could decline if we write-off intangible assets, such as goodwill.

As a result of purchase accounting for our various acquisitions, our balance sheet at December 31, 2007
contains goodwill of $1,033.3 million and other intangible assets, net of accumulated amortization, of $152.7
million (including indefinite lived intangibles of $52.8 million). In accordance with Statement of Financial
Accounting Standards No. 142 “Goodwill and Other Intangible Assets” (“SFAS No. 142”), we evaluate on an
ongoing basis whether facts and circumstances indicate any impairment of the value of indefinite-lived intangible
assets such as goodwill. As circumstances after an acquisition can change, we may not realize the value of these
intangible assets. If we were to determine that a significant impairment has occurred, we would be required to
incur non-cash write-offs of the impaired portion of goodwill and other unamortized intangible assets, which
could have a material adverse effect on our results of operations in the period in which the write-off occurs.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

We lease office space for our corporate offices in Lake Forest, Illinois. In North America we own or lease 3
ETD processing facilities, 12 incineration processing facilities, 34 autoclave processing facilities and 4 other
processing facilities. All of our processing facilities also serve as collection sites. We own or lease 93 additional
transfer and collection sites and 20 additional sales/administrative sites. In Europe we own or lease 10
incineration processing facilities and 9 autoclave processing facilities. We also lease 5 additional transfer and
collection sites and 2 administrative sites. In Argentina we own or lease one administrative site, one ETD
processing facility and 5 processing facilities, which use a combination of both incineration and autoclave
treatments. We consider that these processing facilities are adequate for our present and anticipated needs.

We do not own or operate any landfills or any other type of disposal site. After processing, all remaining

waste materials are transported to unaffiliated third parties for permanent disposal.

Item 3. Legal Proceedings

We operate in a highly regulated industry and must deal with regulatory inquiries or investigations from
time to time that may be instituted for a variety of reasons. We are also involved in a variety of civil litigation
from time to time.

12

In November 2007, the arbitrator issued a final award in arbitration proceedings in Australia with SteriCorp
Limited that we have previously reported. The arbitrator awarded Stericycle $8.2 million USD on our claim
against SteriCorp for payments due under certain convertible notes and awarded SteriCorp $14.5 million USD on
its claim that we failed to supply SteriCorp with equipment conforming to specifications under an equipment
supply agreement. The final award also requires us to pay two-thirds of SteriCorp’s arbitration costs. An estimate
of these amounts has been made and accrued for in our consolidated financial statements. The net effect of the
various components of the final arbitration award was a charge of $13.9 million to our income statement
identified as “Arbitration award and related costs.”

A United Kingdom subsidiary of ours is currently involved in arbitration proceedings with Daniels
Corporation (UK) Limited over White Rose Sharpsmart Limited, a joint venture in which our subsidiary has a
50% interest. We do not believe that these proceedings are material.

Item 4. Submission of Matters to a Vote of Security Holders

No matter was submitted to a vote of our stockholders during the fourth quarter of 2007.

Supplemental Information

Executive Officers of the Registrant

The following table contains certain information regarding our five current executive officers:

Name

Position

Mark C. Miller . . . . . . . . . . . . . . . . . President, Chief Executive Officer and Director
Richard T. Kogler . . . . . . . . . . . . . . . Executive Vice President and Chief Operating Officer
Frank J.M. ten Brink . . . . . . . . . . . . . Executive Vice President and Chief Financial Officer
Richard L. Foss . . . . . . . . . . . . . . . . . Executive Vice President, Corporate Development
Shan S. Sacranie . . . . . . . . . . . . . . . . Executive Vice President, International
Michael J. Collins . . . . . . . . . . . . . . . President, Stericycle Return Management Services

Age

52
48
51
53
55
51

Mark C. Miller has served as our President and Chief Executive Officer and a director since joining us in
May 1992. From May 1989 until he joined us, Mr. Miller served as vice president for the Pacific, Asia and Africa
in the International Division of Abbott Laboratories, which he joined in 1976 and where he held a number of
management and marketing positions. Mr. Miller received a B.S. degree in computer science from Purdue
University, where he graduated Phi Beta Kappa.

Richard T. Kogler joined us as Chief Operating Officer in December 1998. From May 1995 through
October 1998, Mr. Kogler was vice president and chief operating officer of American Disposal Services, Inc., a
solid waste management company. From October 1984 through May 1995, Mr. Kogler served in a variety of
management positions with Waste Management, Inc. Mr. Kogler received a B.A. degree in chemistry from
St. Louis University.

Frank J.M. ten Brink has served as our Executive Vice President, Finance and Chief Financial Officer since
June 1997. From 1991 until 1996 he served as chief financial officer of Hexacomb Corporation, and from 1996
until joining us, he served as chief financial officer of Telular Corporation. Prior to 1991, he held various
financial management positions with Interlake Corporation and Continental Bank of Illinois. Mr. ten Brink
received a B.B.A. degree in international business and a M.B.A. degree in finance from the University of
Oregon.

13

Richard L. Foss has served as our Executive Vice President for Corporate Development since February
2003. From 1999 to 2002, Mr. Foss was a vice president and director of worldwide product marketing in the
personal communication sector at Motorola Inc., and from 1977 until 1999, he held a number of management and
marketing positions at The Procter & Gamble Company, including serving as a vice president and general
manager in the health care segment. Mr. Foss received a B.S. degree in chemistry and an M.B.A degree from
Rensselear Polytechnic Institute.

Shan S. Sacranie joined us in May 2003 and became our Executive Vice President, International in
November 2003. From 2001 to 2002 he was chief executive for Appliance Controls Group, Inc. and from 1995 to
2001, he was president of Oak Industries Inc. From 1978 to 1995 he held a number of management positions for
Honeywell. Mr. Sacranie holds a BA degree (Hons) in economics from the University of Bombay, an M.B.A.
degree from Minnesota State University and a J.D. from the William Mitchell College of Law.

Michael J. Collins has served as President of our Return Management Services Division since June 2006.
Prior to joining us, he served at Abbott Laboratories, a diversified health care company, which he joined in 1982
and where he held a number of management and marketing positions, most recently as vice president, medical
products group health systems. Mr. Collins received a B.A. degree in business and education from the University
of New Haven and a M.B.A. degree in business administration from National University.

14

PART II.

Item 5. Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters

As of February 21, 2007, we had approximately 194 stockholders of record. The Company’s stock trades on

the NASDAQ National Market under the ticker symbol SRCL.

During the quarter ended June 30, 2007 our shareholders approved the increase in our authorized shares of
common stock from 80,000,000 shares to 120,000,000 shares. In addition, our Board of Directors authorized a
2-for-1 stock split. The stock split was in the form of a stock dividend of one share payable on May 31, 2007 in
respect of each share of common stock outstanding on the record date of May 17, 2007. Historic share and per
share amounts have been adjusted to reflect the stock split.

The following table provides the high and low sales prices of our Common Stock for each calendar quarter

during our two most recent fiscal years:

Quarter

First quarter 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Second quarter 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third quarter 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth quarter 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

First quarter 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Second quarter 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third quarter 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth quarter 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

High

Low

$33.81
34.50
34.90
$37.81

$41.12
45.59
57.16
$61.87

$28.64
30.65
30.54
$33.00

$36.59
40.78
43.27
$52.04

We did not pay any cash dividends during 2007 and have never paid any dividends on our common stock.
We currently expect that we will retain future earnings for use in the operation and expansion of our business and
do not anticipate paying any cash dividends in the foreseeable future. See Item 7, “Management’s Discussion and
Analysis of Financial Condition and Results of Operations.”

In May 2002 our Board of Directors authorized the Company to repurchase up to 6,000,000 shares of our
common stock, in the open market or through privately negotiated transactions, at times and in amounts in the
Company’s discretion.

In February 2005, at a time when we had purchased a total of 2,956,860 shares, the Board authorized us to

purchase an additional 2,956,860 shares.

In February 2007, at a time when we had purchased an additional 3,142,080 shares since the prior increase

in authorization, the Board authorized us to purchase up to an additional 3,142,080 shares.

In May 2007, at a time when we had purchased an additional 1,187,142 shares since the prior increase in
authorization, the Board authorized us to purchase up to an additional 1,187,142 shares, thereby again giving the
Company the authority to purchase up to a total of 6,000,000 additional shares.

15

The following table provides information about our purchases of shares of our common stock during the

year ended December 31, 2007:

Issuer Purchase of Equity Securities

Total
Number of Share
(or Units)
Purchased

0
264,000
915,572
7,570
0
283,996
39,965
717,254
0
158,314
1,600
0

Average
Price
Paid per
Share
(or Unit)

$

$

0
39.30
38.99
40.53
0
43.25
43.46
48.49
0
53.17
55.04
0

Number of Shares
(or Units)
Purchased as Part
of Publicly
Announced Plans
or Programs

Maximum Number
(or Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs

0
264,000
915,572
0
0
283,996
39,965
717,254
0
158,314
1,600
0

2,857,920
5,736,000
4,820,428
4,812,858
6,000,000
5,716,004
5,676,039
4,958,785
4,958,785
4,800,471
4,798,871
4,798,871

Period

January 1 - January 31, 2007 . . . . . . . . . . . . . . . .
February 1 - February 28, 2007 . . . . . . . . . . . . . .
March 1 - March 31, 2007 . . . . . . . . . . . . . . . . . .
April 1 - April 30, 2007 . . . . . . . . . . . . . . . . . . . .
May 1 - May 31, 2007 . . . . . . . . . . . . . . . . . . . . .
June 1 - June 30, 2007 . . . . . . . . . . . . . . . . . . . . .
July 1 - July 31, 2007 . . . . . . . . . . . . . . . . . . . . . .
August 1 - August 31, 2007 . . . . . . . . . . . . . . . . .
September 1 - September 30, 2007 . . . . . . . . . . .
October 1 - October 31, 2007 . . . . . . . . . . . . . . . .
November 1 - November 30, 2007 . . . . . . . . . . . .
December 1 - December 31, 2007 . . . . . . . . . . . .

Equity Compensation Plans

The following table summarizes information as of December 31, 2007 relating to our equity compensation
plans pursuant to which stock option grants, restricted stock awards or other rights to acquire shares of our
common stock may be made or issued:

Equity Compensation Plan Information

Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options,
Warrants and
Rights
(a)

Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights
(b)

Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans (Excluding
Securities Reflected in
Column (a))
(c)

Plan Category

Equity compensation plans approved by our security

holders(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4,757,128

Equity compensation plans not approved by our

security holders(2) . . . . . . . . . . . . . . . . . . . . . . . . . .

2,501,667

$27.42

$21.66

2,601,536

403,086

(1) These plans consist of our 2005 Incentive Stock Plan, 1997 Stock Option Plan, , Directors Stock Option

Plan and the Employee Stock Purchase Plan.

(2) The only plan in this category is our 2000 Nonstatutory Stock Option Plan.

In 2000, our Board of Directors approved the 2000 Nonstatutory Stock Option Plan (the “2000 Plan”),
which authorized the granting of nonstatutory stock options for 7,000,000 shares of our common stock to
employees (but not to officers or directors). See Note 12 to the Consolidated Financial Statements for a
description of this plan.

16

Performance Graph

The following graph compares the cumulative total return (i.e., stock price appreciation plus dividends) on
our common stock over the five-year period ending December 31, 2007 with the cumulative total return for the
same period on the Nasdaq National Market Composite Index, the Russell 3000 Index and an index of a peer
group of companies that we selected consisting of Allied Waste Industries, Inc., SRI/Surgical Express, Inc.
(formerly Sterile Recoveries, Inc.), Steris Corporation and Waste Management, Inc. The graph assumes that $100
was invested on December 31, 2002 in our common stock and in the stock represented by each of the three
indexes, and that all dividends were reinvested.

The stock price performance of our common stock reflected in the following graph is not necessarily

indicative of future performance.

Stericycle, Inc.

Nasdaq NM Composite

Russell 3000 Index

Peer Group

$400.00

$350.00

$300.00

$250.00

$200.00

$150.00

$100.00

$50.00

$0.00

12/31/02

12/31/03

12/31/04

12/31/05

12/31/06

12/31/07

17

Item 6. Selected Consolidated Financial Data

Statement of Income Data(1)
Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income from operations . . . . . . . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income applicable to common stock . . . . . .
Diluted net income per share of common

stock(2)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . .
Other Data
Cash provided by operating activities . . . . . . . .
Cash used in investing activities . . . . . . . . . . . .
Cash (used in)/ provided by financing

Years Ended December 31,

2007

2006(3)

2005

2004

2003

Dollars in thousands, except per share data

$ 932,767
224,544
118,378
118,378

$ 789,637
201,762
105,270
105,270

$ 609,457
166,532
67,154
67,154

$ 516,228
145,655
78,178
78,178

$453,225
126,397
65,781
65,781

1.32
31,137

1.16
27,036

0.74
21,431

0.85
21,803

0.71
17,255

$ 174,042
(135,261)

$ 160,162
(201,425)

$

94,327
(156,001)

$ 114,611
(105,093)

$123,887
(57,635)

activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(32,635)

52,547

59,500

(6,941)

(66,820)

Balance Sheet Data(1)
Cash, cash equivalents and short-term

investments . . . . . . . . . . . . . . . . . . . . . . . . . .
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt, net of current portion . . . . . . .
Convertible redeemable preferred stock . . . . . .
Shareholders’ equity . . . . . . . . . . . . . . . . . . . . .

$

18,364
1,608,159
613,781
—
$ 714,075

$

16,040
1,327,906
443,115
—
$ 625,081

$

8,545
1,047,660
348,841
—
$ 521,634

$

7,949
834,141
190,431
—
$ 495,372

$

7,881
707,462
163,016
20,944
$407,820

(1) See Note 3 to the Consolidated Financial Statements for information concerning our acquisitions during the

three years ended December 31, 2007.

(2) See Note 11 to the Consolidated Financial Statements for information concerning the computation of net

income per common share.
•

In 2007, net income includes nonrecurring costs (net of tax) of $9.3 million, of which $7.7 million were
net non-cash items. These costs negatively impacted diluted earnings per share (“EPS”) by $0.10,
related to the following:
i. We recognized legal settlement expense related to the arbitration award in Australia, including

expected arbitration cost reimbursements to be paid in 2008;

ii. We wrote down our investment in Medam, B.A., an Argentine joint venture. The write down of
our investment in Argentina was a result of the legal restructuring of the business operations;
iii. We wrote down the White Rose Environmental tradename as a result of the name change of our

subsidiary in the United Kingdom;

iv. We wrote down the permit intangible for a treatment facility in the United Kingdom that was no

longer being used;

v. We wrote down equipment that had been permanently idled;
vi. We recorded a gain on the divestiture of selected assets of Sterile Technologies, Ltd., one of our

subsidiaries in the United Kingdom;

vii. We received proceeds from two of our insurance carriers for coverage related to the 3CI Complete

Compliance Corporation (“3CI”) class action litigation settlement;

viii. We divested the over the counter products portion of our Scherer Labs assets which resulted in a

gain.

•

In 2006, net income includes costs (net of tax) related to a fixed asset write-down of equipment of $0.2
million, write-down of an investment in securities of $0.6 million, partially offset by income recorded
from insurance proceeds related to the 3CI settlement of $0.6 million. The net amount of $0.2 million
did not affect EPS.

18

•

•

•

In 2005, net income includes costs (net of tax) related to the 3CI preliminary settlement of class action
litigation of $23.4 million, South Africa note receivable write-down of $1.5 million, fixed asset
impairments of $0.5 million, settlement of licensing litigation of $1.1 million, and items related to debt
restructuring of $0.3 million which negatively impacted EPS by $0.30 per share. Of the total of $26.8
million of such items, $3.4 million were non-cash items.
In 2004, net
income includes fixed asset write-offs of $0.7 million, and items related to debt
restructuring and redemption of senior subordinated debt of $2.8 million that negatively impacted EPS
by $0.04 per share.
In 2003, net income includes debt restructuring and subordinated debt repurchase of $2.0 million (net
of tax), which negatively impacted EPS by $0.02 per share.

(3) On January 1, 2006, we adopted the provisions of SFAS No. 123R, “Share-Based Payment” (“SFAS
No. 123R”) using the modified prospective method to account for stock compensation costs. SFAS
No. 123R requires the measurement and recognition of compensation expense for all stock-based payment
awards made to our employees and directors. During the years ended December 31, 2007 and 2006, we
recognized stock compensation expense (net of tax) of $6.6 million and $6.5 million, respectively. See Note
12 to the Consolidated Financial Statements for additional information related to stock compensation
expense.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation

The following discussion of our financial condition and results of operations should be read in conjunction

with our consolidated financial statements and related notes in Item 8 of this Report.

Introduction

We are in the business of managing regulated waste and providing an array of related services. We operate

in the United States, the United Kingdom, Mexico, Canada, Ireland and Argentina.

For large-quantity generators of regulated waste such as hospitals and for pharmaceutical companies and
institutional medical waste management services; our Bio Systems® sharps
distributors, we offer: our
management services to reduce the risk of needle sticks; a variety of products and services for infection control;
and our regulated returns management services for expired or recalled products.

For small-quantity generators of regulated waste such as doctors’ offices and for retail pharmacies, we offer:
our medical waste management services; our Steri-Safe® Occupational Safety and Health Act and HIPAA
compliance programs; a variety of products and services for infection control; and our pharmaceutical returns
services for expired or recalled pharmaceuticals.

We operate integrated national medical waste management networks in the United States, Canada, Mexico,
Argentina, the United Kingdom and Ireland. Our national networks include a total of 78 processing or combined
processing and collection sites and 98 additional transfer, collection or combined transfer and collection sites.

Our medical waste processing technologies include autoclaving, our proprietary ETD, chemical treatment

and incineration.

As of December 31, 2007, we served approximately 394,600 customers, of which approximately 384,900

were small quantity customers and approximately 9,700 were large quantity customers.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our
consolidated financial statements, which have been prepared in accordance with accounting principles generally

19

accepted in the United States. The preparation of these financial statements requires that we make estimates and
judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure
of contingent assets and liabilities. We believe that of our significant accounting policies (see Note 2 to our
consolidated financial statements), the following ones may involve a higher degree of judgment on our part and
greater complexity of reporting.

Revenue Recognition: We recognize revenues for our regulated waste services at the time of waste
collection. Payments received in advance are deferred and recognized as services are provided. Revenues from
regulated returns management services are recorded at the time services are performed. Royalty revenues are
calculated based on measurements specified in each contract or license and revenues are recognized at the end of
each reporting period when the activity being measured has been completed. Revenues from product sales are
recognized at the time the goods are shipped to the ordering customer. Software licensing revenues are
recognized on a prorated basis over the term of the license agreement. We do not have any contracts in a loss
position. Losses would be recorded when known and estimable for any contracts that should go into a loss
position.

Goodwill and Other Identifiable Intangible Assets: Goodwill associated with the excess purchase price
over the fair value of assets acquired is not amortized. We have determined that our permits have indefinite lives
and, accordingly are not amortized. This position is in accordance with Statement of Financial Accounting
Standards No. 142, “Goodwill and Other Intangible Assets” (“SFAS No. 142”). See Note 9 Goodwill and Other
Intangible Assets for additional information.

Our balance sheet at December 31, 2007 contains goodwill of $1,033.3 million. In accordance with SFAS
No. 142, we evaluate on at least an annual basis, using the fair value of reporting units, whether goodwill is
impaired. If we were to determine that a significant impairment has occurred, we would be required to incur
non-cash write-offs of the impaired portion of goodwill that could have a material adverse effect on our results of
operations in the period in which the write-off occurs. We use the market value of our stock compared to book as
the current measurement of total fair value of our company. The performance of each of our reporting units is
compared to that fair value ratio, and any unforeseen material drop in our stock price may be an indicator of a
potential impairment of goodwill. The results of the 2007 impairment test conducted in June 2007 did not show
any impairment of goodwill, and no events have occurred since that time that indicate that an impairment
situation exists.

Our permits are currently tested for impairment annually at December 31, or more frequently if
circumstances indicate that they may be impaired. We use a discounted income approach model as the current
measurement of the fair value of the permits. The estimate of income is based upon, among other things, certain
assumptions about expected future operating performance and an appropriate discount rate determined by
management. Our estimates of discounted income may differ from actual income due to, among other things,
inaccuracies in economic estimates. In the second quarter of 2007 we wrote down approximately $0.2 million for
a permit in the United Kingdom due to a management decision to move waste processing to an alternate location.
The results of the 2007 impairment test did not show any impairment of our remaining permits and no events
have occurred since that time that would indicate an impairment situation exists.

Other

identifiable intangible assets,

tradenames and covenants
such as customer
not-to-compete, are currently amortized using the straight-line method over their estimated useful lives. We have
determined that our regulated waste customer relationships have between 20-year and 40-year lives based on the
specific type of relationship. This determination was based on an independent study performed on our customer
relationships. Although the regulated waste management business is highly competitive we have been able to
maintain high customer retention through contracts with automatic renewal provisions and excellent customer
service.

relationships,

The valuation of our contractual customer relationships was derived using a discounted income approach
valuation model similar to the method used for permit impairment testing mentioned earlier. These assets are

20

reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an
asset may be less than its undiscounted estimated future cash flows. There have been no indicators of impairment
of these intangibles (see Note 9 to our consolidated financial statements).

Income Taxes: Deferred income tax liabilities and assets are determined based on the differences between
the financial statement and income tax basis of assets and liabilities using enacted tax rates in effect for the year
in which the differences are expected to reverse. To provide for certain potential tax exposures, we maintain a
reserve for specific tax contingencies, the balance of which management believes is adequate.

In September 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation
No. 48, “Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109”
(“FIN 48”). This interpretation clarifies the accounting for uncertainty in income taxes recognized in an
enterprise’s financial statements in accordance with Statement of Financial Accounting Standards (“SFAS”)
No. 109, “Accounting for
Income Taxes”. This Interpretation prescribes a recognition threshold and
measurement attribute for the financial statement recognition and measurement of a tax position taken, or
expected to be taken, in a tax return. This interpretation also provides guidance on de-recognition, classification,
interest and penalties, accounting in interim periods, disclosure and transition. We adopted the provisions of
FIN 48 on January 1, 2007. The adoption of FIN 48 did not have a material impact on our consolidated financial
statements.

Accounts Receivable: Accounts receivable consist primarily of amounts due to us from our normal business
activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on
the contractual terms with the customer. We maintain an allowance for doubtful accounts to reflect the expected
uncollectibility of accounts receivable based on past collection history and specific risks identified among
uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when we have
determined that the receivable will not be collected and/or when the account has been referred to a third party
collection agency. No single customer accounts for more than 2% of our revenues.

Insurance: Our insurance for worker’s compensation, vehicle liability and physical damage, and employee-
related health care benefits is obtained using high deductible insurance polices. A third-party administrator is
used to process all such claims. We require all workers’ compensation, vehicle liability and physical damage
claims to be reported within 24 hours. As a result, we accrue our worker’s compensation, vehicle and physical
damage liability based upon the claim reserves established by the third-party administrator at the end of each
reporting period. Our employee health insurance benefit liability is based on our historical claims experience
rate. Our earnings would be impacted to the extent that actual claims vary from historical experience. We review
our accruals associated with the exposure to these liabilities for adequacy at the end of each reporting period.

Litigation: We operate in a highly regulated industry and deal with regulatory inquiries or investigations
from time to time that may be instituted for a variety of reasons. We are also involved in a variety of civil
litigation from time to time. Settlements from litigation would be recorded when known, probable and estimable.

Stock Option Plans: We have issued stock options to employees and directors as an integral part of our
compensation programs. On January 1, 2006, we adopted the provisions of SFAS No. 123R, “Share-Based
Payment” (“SFAS No. 123R”) using the modified prospective method to account for stock compensation costs.
SFAS No. 123R requires the measurement and recognition of compensation expense for all stock-based payment
awards made to our employees and directors. Under the fair value recognition provisions of SFAS No. 123R,
stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as
expense over the vesting period. Determining the fair value of stock-based awards at the grant date requires
considerable judgment, including estimating expected volatility, expected term and risk-free rate. Our expected
volatility is based upon historical experience. The expected term of the stock options is based upon a measure of
historical volatility of our stock price. The risk-free interest rate assumption is based upon the U.S. Treasury
yield rates of a comparable period. If factors change and we employ different assumptions, stock-based
compensation expense may differ significantly from what we have recorded in the past.

21

New Accounting Pronouncements: For information about recently issued accounting pronouncements, see

Note 2. “Summary of Significant Accounting Policies” in the Notes to the Consolidated Financial Statements.

Year Ended December 31, 2007 Compared to Year Ended December 31, 2006

The following summarizes the Company’s operations:

Years Ended December 31,

2007

2006

$

%

$

%

in thousands, except per share data

Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$932,767
491,789
23,057

100.0
52.7
2.5

$789,637
419,689
20,081

100.0
53.1
2.5

Total cost of revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

514,846

Gross profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative expenses . . . . . . . . . . . . . . . . . . . . . . .
Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

417,921
168,657
4,423
3,657

Total selling, general and administrative expenses . . . . . . . . . . . . . . . . . . .

176,737

Gain on sale of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of fixed assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Arbitration award and related costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisition integration expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Income from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-down of investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Insurance proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Earnings per share—Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(2,099)
2,269
1,261
13,904
1,305

224,544
2,930
(3,300)
32,375
72,862
$118,378
1.32
$

55.2

44.8
18.1
0.5
0.4

18.9

(0.2)
0.2
0.1
1.5
0.1

24.1
0.3
(0.4)
3.5
7.8
12.7

439,770

349,867
137,411
3,989
2,966

144,366

—
—
300
—
3,439

201,762
1,000
(1,025)
27,061
67,304
$105,270
1.16
$

55.7

44.3
17.4
0.5
0.4

18.3

—
—
0.0
—
0.4

25.6
0.1
(0.1)
3.4
8.5
13.3

Revenues: Our revenues increased $143.1 million, or 18.1%, to $932.8 million in 2007 from $789.6 million
in 2006. Domestic revenues increased $105.0 million, or 17.0%, to $721.4 million from $616.4 million in 2006
as internal growth for domestic small account customers increased by approximately $37.1 million, over 10%,
driven by an increase of Steri-Safe customers. Revenues from domestic large account customers increased
approximately $13.1 million, or over 6% as we increased the total number of accounts. Returns Management
Services increased revenues compared to 2006 by over $22.3 million from internal growth due to larger than
expected recall volumes. Domestic acquisitions less than one year old added an additional $32.5 million in
revenues compared to 2006.

International revenues in 2007 were $211.4 million, compared to $173.2 million in 2006, an increase of
$38.1 million or 22.0%. Internal growth, currency rate fluctuations, acquisitions, and the divestiture of some
plants in the United Kingdom, impact the comparison of 2007 to 2006. Internal growth was $16.2 million. The
effect of exchange rates favorably impacted international 2007 revenues by $11.8 million as foreign currencies
appreciated against the U.S. dollar, acquisitions less than one year old favorably impacted revenues by $24.5
million, while the divestiture at a gain of selected Sterile Technologies Group, Ltd., (“STG”) plants in the first
quarter of 2007 negatively impacted the comparison to 2006 by $14.4 million.

22

Cost of Revenues: Our 2007 cost of revenues increased $75.1 million, or $17.1%, to $514.8 million
compared to $439.8 million in 2006. Domestic cost of revenues increased $47.4 million, or 14.7%, to $369.9
million in 2007 compared to $322.6 million for 2006. International cost of revenues increased $27.7 million, or
23.6%, to $144.9 million in 2007 compared to $117.2 million in 2006.

Our gross margin percentage increased to 44.8% during 2007 from 44.3% during 2006. Domestic gross
margin percentage improved 1.0% to 48.7% during 2007 from 47.7% in 2006. Our gross margin increase was
primarily the result of increased number of small quantity customers, which have a better gross margin. Domestic
energy and transportation costs increased in 2007, which were partially offset by higher revenues related to fuel
surcharges.

International gross margin decreased 0.9% in 2007 compared to 2006, primarily due to acquisitions whose
margins are lower. In general, international gross margins are lower than domestic gross margins because the
international operations have less penetration into the small quantity generator market, which has a better gross
margin. Historically, the international operations have had most of their revenues from large national healthcare
hospitals. As the international segment increases, consolidated gross margins receive downward pressure due this
“business mix”, which can be offset by additional international small quantity market penetration, integration
savings and domestic business expansion.

Selling, General and Administrative Expenses: In 2007, our selling, general and administrative (“SG&A”)
expenses increased $32.4 million, or 22.4%, to $176.7 million from $144.4 million in 2006. Amortization and
depreciation expense, as a percentage of revenue, did not change from 2006 to 2007. Domestically, 2007 SG&A
increased $26.6 million, or 22.8%, to $143.1 million from $116.6 million in 2006. The increase was primarily
due to spending related to market penetration for our Bio Systems® sharps management program and investments
in the Steri-Safe and returns management services.

Internationally, our SG&A increased $5.8 million, or 20.7%, in 2007 to $33.6 million from $27.8 million in
2006, mostly due to foreign exchange fluctuations (higher dollar costs as the dollar weakened versus other
currencies). As a percentage of revenue, international SG&A decreased 0.2%. This decrease reflects the ongoing
efforts to integrate our businesses in the United Kingdom and Argentina.

Income from Operations: Income from operations increased by $22.8 million, or 11.3%, to $224.5 million
in 2007 from $201.8 million in 2006. Comparisons of income from operations between 2007 and 2006 are
affected by various charges not considered part of our day-to-day operations. During the year ended
December 31, 2007 we had charges totaling $17.4 million related to permit write-offs, fixed asset write-offs and
settlement of arbitration proceedings in Australia. Those charges were partially offset by gains of $2.1 million
from the sale of assets of STG and of Scherer Labs. During the year ended December 31, 2006, we recorded
expenses of $0.3 million related to fixed asset write downs.

Domestically, our income from operations increased $17.7 million, or 10.1%, to $192.8 million from $175.1
million in 2006. Internationally our income from operations increased $5.1 million, or 19.1%, to $31.7 million
from $26.7 million in 2006.

Interest Expense and Interest Income: Interest expense increased to $34.0 million during 2007 from $28.4
million during 2006. The increase of $5.6 million is related to higher debt levels incurred to finance acquisitions
and stock repurchases. Interest income was $1.6 million during 2007 and $1.4 million during 2006.

Write-down of Investment: During 2007 we had a $2.9 million non-cash write-down of our investment in
Medam B.A., an Argentine medical waste processing company. The write-down was due to a legal restructuring
of the Medam B.A. operations. Stericycle now is the sole owner of Medam B.A. During 2006 we had a $1.0
million non-cash write-down of an investment in securities.

23

Proceeds from Insurance: During 2007 we received $3.3 million of insurance proceeds related to the 3CI
litigation settled in 2005. During 2006 we received $1.0 million of insurance proceeds related to the 3CI
litigation settled in 2005.

Income Tax Expense: Income tax expense for the years 2007 and 2006 reflects an effective tax rate of

approximately 38.1% and 39.0%, respectively, for federal and state income taxes.

Year Ended December 31, 2006 Compared to Year Ended December 31, 2005

The following summarizes the Company’s operations:

Years Ended December 31,

2006

2005

$

%

$

%

in thousands, except per share data

Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$789,637
419,689
20,081

100.0
53.1
2.5

$609,457
324,988
16,432

100.0
53.3
2.7

Total cost of revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

439,770

Gross profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative expenses . . . . . . . . . . . . . . . . . . . . .
Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

349,867
137,411
3,989
2,966

Total selling, general and administrative expenses . . . . . . . . . . . . . . . . .

144,366

Licensing legal settlement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of fixed assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisition integration expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—
300
3,439

Income from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-down of security investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-down of note receivable with joint venture . . . . . . . . . . . . . . . . .
3CI legal settlement (2005)/ proceeds from insurance (2006) . . . . . . . .
Net interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Earnings per share—diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

201,762
1,000
—
(1,025)
27,061
67,304
$105,270
1.16
$

55.7

44.3
17.4
0.5
0.4

18.3

—
0.0
0.4

25.6
0.1
—
(0.1)
3.4
8.5
13.3

341,420

268,037
93,033
3,403
1,596

98,032

1,823
872
778

166,532
—
2,495
36,481
12,247
44,826
$ 67,154
0.74
$

56.0

44.0
15.3
0.6
0.3

16.1

0.3
0.1
0.1

27.3
—
0.4
6.0
2.0
7.4
11.0

Revenues: Our revenues increased $180.2 million, or 29.6%, to $789.6 million in 2006 from $609.5 million
in 2005. Domestic revenues increased $108.2 million, or 21.3%, to $616.4 million from $508.3 million in 2005
as internal growth for domestic small account customers increased by approximately $33.5 million, or 11%, and
internal growth for large quantity customers increased by approximately $16.5 million, or 9%. Internal growth
for returns management was $7.8 million, and acquisitions less than one year old contributed approximately
$50.4 million to the increase in domestic revenues.

International revenues increased $72.0 million to $173.2 million from $101.2 million in 2005. Internal
growth of
favorable exchange rates, was
approximately $9.4 million, or 9.3%. International acquisitions less than one year old contributed approximately
$59.4 million to the increase in international revenues.

revenues, excluding the $3.2 million effect of

international

Through our acquisition of The Sterile Technologies Group Limited and Habitat Ecologico S.A. in February

2006, we were able to expand our geographic presence outside of North America.

24

Cost of Revenues: Our cost of revenues increased $98.4 million, or 28.8%, to $439.8 million during 2006
from $341.4 million during 2005. Our domestic cost of revenues increased $50.1 million, or 18.3%, to $322.6
million from $272.7 million in 2005, and our international cost of revenues increased $48.3 million to $117.2
million from $68.7 million in 2005. This increase was primarily due to an increase in incremental expenses in
both domestic and international cost of revenues as a result of acquisitions completed during 2006.

Our gross margin percentage increased to 44.3% during 2006 from 44.0% during 2005. Domestic gross
margin increased to 47.7% in 2006 from 46.5% in 2005 and international gross margin increased to 32.2% in
2006 from 31.4% in 2005. The increase in the gross margins of our domestic business was a result of increased
efficiencies and higher margin service add-ons, and the increase in the gross margins of our international
business was a result of continued acquisition integration efficiencies and of leveraging our international
infrastructure. In general, international gross margins are lower than domestic gross margins because the
international operations have less penetration into the small quantity generator market, which has a better gross
margin. Historically, the international operations have had most of their revenues from large national healthcare
hospitals. Margins may be impacted by acquisitions in any period as the revenue may change.

Selling, General and Administrative Expenses: In 2006, our SG&A expenses, less stock compensation
expense, increased $36.5 million, or 37.2%, to $134.5 million from $98.0 million in 2006. Effective January 1,
2006 we adopted SFAS No. 123R using the modified prospective basis, which resulted in a change in the way we
recognize share-based compensation expense, which increased SG&A expenses by $9.8 million or 1.2% as a
percentage of revenue.

Domestically, 2006 SG&A, less stock compensation expense, increased $25.6 million, or 31.6%, to $106.7
million from $81.0 million in 2005. The increase was primarily due to spending related to market penetration for
our Bio Systems® sharps management program and increased investing in growing the Steri-Safe products.
Internationally, our SG&A increased $10.9 million, or 64.0%, in 2006 to $27.8 million from $17.0 million in
2005. The increase was primarily due to the acquisition of STG in February 2006.

Income from Operations: Income from operations increased $35.2 million or 21.2% to $201.8 million
during 2006 from $166.5 million during 2005. The increase was due to higher gross margin partially offset by
higher SG&A expenses. During the year ended December 31, 2006, we recorded expenses of $3.4 million related
to acquisition integration compared to $0.8 million in 2005. Of the $3.4 million of 2006 expense, approximately
$1.1 million related to facility closures; one in the United States and one in the United Kingdom. During the year
ended December 31, 2006 we recorded a $0.3 million non-cash write-down of equipment acquired from 3CI.
During the year ended December 31, 2005 we recorded a non-cash impairment charge of $0.9 million related to
our Springhill, Louisiana building and property. Income from operations as a percentage of revenue decreased to
25.6% during 2006 from 27.3% during 2005 as a result of the factors described above.

Interest Expense and Interest Income: Interest expense increased to $28.4 million during 2006 from $13.0
million during 2005, primarily due to higher debt levels and higher interest rates during the year. Interest income
was $1.4 million during 2006 and $0.8 million during 2005.

Write-down of Investment: During 2006 we had a $1.0 million non-cash write-down of an investment in

securities.

Proceeds from Insurance: During 2006 we received $1.0 million for insurance proceeds related to the 3CI

litigation.

Legal Settlements: During 2005 we incurred $36.5 million in expenses related to the preliminary settlement

of the 3CI class action litigation and related legal expenses.

Write-down of note receivable: During 2005 we wrote-down a $2.5 million note receivable that we had
recorded from the sale of interest in our former South African joint venture when we had determined that the
amount was uncollectible.

25

Income Tax Expense: Income tax expense for the years 2006 and 2005 reflects an effective tax rate of
approximately 39.0% and 40.0%, respectively, for federal and state income taxes. The legal settlement negatively
impacted our 2005 effective tax rate by 1.0%.

Liquidity and Capital Resources

On August 24, 2007, we amended and restated our $650.0 million senior unsecured revolving credit facility
maturing in July 2011. The credit facility was increased to $850.0 million and the maturity was extended to
August 24, 2012. At December 31, 2007 the margin for interest rates on borrowings under our new credit facility
was 0.0% on base rate (at the higher of (i) the federal funds rate plus 0.5% or (ii) the prime rate) loans and
0.625% on LIBOR loans. Our credit facility requires compliance with various financial, reporting and other
covenants and restrictions, including a restriction on dividend payments. At December 31, 2007, we were in
compliance with all of our financial debt covenants.

As of December 31, 2007, we had $465.4 million of borrowings outstanding under our senior unsecured
credit facility, which includes foreign currency borrowings of $16.0 million. In addition, we had $139.4 million
committed to outstanding letters of credit. The weighted average rate of interest on the unsecured revolving
credit facility was 5.53% per annum. At December 31, 2007 we had $170.4 million in other debt outstanding,
which includes promissory notes issued in connection with acquisitions during 2004 through 2007, other foreign
subsidiary bank debt and $1.7 million in capital leases.

Working Capital: At December 31, 2007, our working capital was $60.6 million compared to working
capital of $76.6 million at December 31, 2006. Working capital decreased by $26.5 million due to the completion
of the divestiture of selected STG plants that were classified as “Assets of disposal group held for sale” and
“Liabilities of disposal group held for sale” and presented as current assets and current liabilities at December 31,
2006. Working capital increased by $27.0 million due to higher accounts receivable related to increased
revenues, and decreased $15.0 million due to higher accounts payable.

Net Cash Provided or Used: Net cash provided by operating activities was $174.0 million during 2007
compared to $160.2 million for 2006. The increase was primarily due to increased net income and accounts
payable.

Net cash used in investing activities during 2007 was $135.3 million compared to $201.4 million used in
2006. The difference is due to approximately $49.2 million less paid for acquisitions and $26.5 million received
from the divestiture of selected STG plants completed in February 2007, partially offset by $12.0 million in
increased capital expenditures.

At December 31, 2007 we had approximately 9% of our treatment capacity in North America in incineration
and approximately 91% in non-incineration technologies, such as autoclaving and our proprietary patented ETD
technology. The implementation of our commitment to move away from incineration in North America may
result in a write-down of the incineration equipment as and when we close incinerators that we are currently
operating. The net book value of our North American incinerators was approximately $7.3 million, or 0.5% of
our total assets. Our commitment to move away from incineration in North America is in the nature of a goal to
be accomplished over an undetermined number of years. Because of uncertainties relating, among other things, to
customer education and acceptance and legal requirements to incinerate portions of the medical waste, we do not
have a timetable for this transition or specific plans to close any of our existing incinerators.

Net cash used in financing activities was $32.6 million during 2007 compared to net cash provided of $52.5
million for 2006. Approximately $60.9 million of this difference is the result of an increase in the repurchase of
and cancellation of common stock in 2007 compared to 2006, while another $18.5 million is related to the pay
down of long-term debt.

26

Contractual Cash Commitments: The following table displays our future contractual cash commitments:

Payments due by period (dollars in thousands)

Total

2008

2009-
2010

2011-
2012

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt(1)
Capital lease obligations(1) . . . . . . . . . . . . . . . . . . . . . .
Purchase obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term liabilities(1)(2) . . . . . . . . . . . . . . . . . . .

$782,585
1,875
1,057
138,568
2,869

$53,442
683
642
31,083
799

$106,955
990
415
50,208
1,349

$549,577
202
—
28,552
556

2013 and
After

$ 72,611
—
—
28,725
165

Total contractual cash obligations . . . . . . . . . . . . . . . . .

$926,954

$86,649

$159,917

$578,887

$101,501

(1) The long-term debt, capital lease and other long-term liabilities items include both the future principal
payment amount as well as an amount calculated for expected future interest payments. For long-term debt
with variable rates of interest, management used judgment to estimate the future rate of interest. Other long-
term liabilities include amounts related to non-compete agreements.

(2) Excludes payments for unrecognized tax benefits. Based on the contingent and uncertain nature of our
liability for unrecognized tax benefits, we are unable to make an estimate of the period of potential
settlement, if any, with respective taxing authorities.

At December 31, 2007 we had $139.4 million in stand-by letters of credit issued.

We anticipate that our operating cash flow, together with borrowings under our senior secured credit
facility, will be sufficient to meet our anticipated future operating expenses, capital expenditures and debt service
obligations as they become due during the next 12 months and the foreseeable future.

Guarantees: We have guaranteed a loan to JPMorganChase Bank N.A. on behalf of Shiraishi-Sogyo Co.
Ltd (“Shiraishi”). Shiraishi is a customer in Japan that is expanding their medical waste management business
and has a six-month loan with a current balance of $4.3 million with JPMorganChase Bank N.A. that expires in
May 2008. Management currently believes no amount will be paid under the guarantee.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

We are subject to market risks arising from changes in interest rates. Our potential additional interest expense
over one year that would result from a hypothetical, instantaneous and unfavorable change of 100 basis points in the
interest rate on all of our variable rate obligations would be approximately $4.9 million on a pre-tax basis.

We have exposure to currency exchange rate fluctuations between the U.S. dollar and U.K. pound sterling
(“GBP”) related to an 11 million GBP inter-company loan to Stericycle International, Ltd., the parent company
of White Rose Environmental. We use cash flow hedge accounting treatment on our forward contracts. Both the
inter-company loan balance and the forward contracts are marked to market at the end of each reporting period
and the impact on the balances is recorded on the balance sheet to other comprehensive income.

We have exposure to commodity pricing for gas and diesel fuel for our trucks and for the purchase of

containers and boxes. We do not hedge these items to manage the exposure.

27

Item 8. Consolidated Financial Statements and Supplemental Data

Management’s Report on Internal Control Over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control
over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) under the
Securities Exchange Act of 1934 as a process designed by, or under the supervision of, a company’s principal
executive and principal financial officers and effected by the company’s board of directors, management and
other personnel,
to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting
principles. The Company’s internal control over financial reporting includes those policies and procedures that:

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the

transactions and dispositions of the assets of the Company;

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and
expenditures of the Company are being made only in accordance with authorizations of management and
directors of the Company; and

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,

use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls
may become inadequate because of changes in conditions, or that the degree of compliance with the policies or
procedures may deteriorate.

The Company’s management assessed the effectiveness of the Company’s internal control over financial
reporting as of December 31, 2007. In making this assessment, management used the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control–Integrated
Framework.

Based on this assessment and those criteria, management concludes that the Company maintained effective

internal control over financial reporting as of December 31, 2007.

The Company’s independent auditors have issued an attestation report on the Company’s internal control

over financial reporting. That report appears on page 29.

Stericycle, Inc.

Lake Forest, IL
February 27, 2008

28

Report of Independent Registered Public Accounting Firm
on Internal Control over Financial Reporting

The Board of Directors and Shareholders of Stericycle, Inc.

We have audited Stericycle, Inc.’s internal control over financial reporting as of December 31, 2007, based
on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (the COSO criteria). Stericycle, Inc.’s management is responsible
for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of
internal control over financial reporting included in the accompanying Management’s Report on Internal Control
over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over
financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether effective internal control over financial reporting was maintained in all material respects. Our
audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a
material weakness exists, testing and evaluating the design and operating effectiveness of internal control based
on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We
believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. A company’s internal control over financial reporting
includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.

In our opinion, Stericycle, Inc. maintained, in all material respects, effective internal control over financial

reporting as of December 31, 2007, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), the consolidated balance sheets of Stericycle, Inc. and Subsidiaries as of December 31, 2007 and
2006, and the related consolidated statements of income, changes in shareholders’ equity, and cash flows for each
of the three years in the period ended December 31, 2007 and our report dated February 27, 2008 expressed an
unqualified opinion thereon.

Chicago, Illinois
February 27, 2008

Ernst & Young LLP

29

Report of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders of Stericycle, Inc.

We have audited the accompanying consolidated balance sheets of Stericycle, Inc. and Subsidiaries as of
December 31, 2007 and 2006, and the related consolidated statements of income, changes in shareholders’
equity, and cash flows for each of the three years in the period ended December 31, 2007. Our audits also
included the financial statement schedule listed in the Index at Item 15(a). These financial statements and
schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on
these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that our audits provide a reasonable basis for our
opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the
consolidated financial position of Stericycle, Inc. and Subsidiaries at December 31, 2007 and 2006, and the
consolidated results of their operations and their cash flows for each of the three years in the period ended
December 31, 2007, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the
related financial statement schedule, when considered in relation to the basic financial statements taken as a
whole, presents fairly in all material respects the information set forth herein.

As disclosed in Note 2 to the consolidated financial statements, the Company changed its method of
accounting for stock-based compensation in accordance with the guidelines provided in Statement of Financial
Accounting Standards No. 123(R) “Share-Based Payment” on January 1, 2006.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), Stericycle, Inc.’s internal control over financial reporting as of December 31, 2007, based on
criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission and our report dated February 27, 2008 expressed an unqualified
opinion thereon.

Ernst & Young LLP

Chicago, Illinois
February 27, 2008

30

STERICYCLE, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
In thousands, except share and per share data

ASSETS
Current assets:

Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable, less allowance for doubtful accounts of $6,157 in 2007 and
$5,411 in 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Assets of disposal group held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Property, plant and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill
Intangible assets, less accumulated amortization of $12,230 in 2007 and $11,454
in 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2007

2006

$

17,108
1,256

$

13,492
2,548

157,435
13,510
—
20,967

210,276

193,039

130,354
16,072
33,674
22,462

218,602

156,953

1,033,333

813,973

152,689
18,822

115,879
22,499

952,351

Total other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,204,844

Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,608,159

$1,327,906

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:

Current portion of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Liabilities of disposal group held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Long-term debt, net of current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Common shareholders’ equity:

Common stock (par value $.01 per share, 120,000,000 shares authorized,

87,410,653 issued and outstanding in 2007, 88,503,930 issued and outstanding
in 2006) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additional paid-in capital
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated other comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

22,003
40,049
75,571
12,095
—

149,718

613,781
125,041
5,544

$

22,681
25,033
75,434
11,662
7,221

142,031

443,115
105,521
12,158

874
197,462
30,520
485,219

714,075

886
252,125
5,229
366,841

625,081

Total liabilities and shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,608,159

$1,327,906

The accompanying notes are an integral part of these financial statements.

31

STERICYCLE, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
In thousands, except share and per share data

Years Ended December 31,

2007

2006

2005

$

932,767

$

789,637

$

609,457

341,420
98,032
1,823
—
—
872
—
778

442,925

166,532

764
(13,011)
—
(447)
(2,495)

(36,481)
(2,882)

(54,552)

111,980
44,826

Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Costs and expenses:

Cost of revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative expenses . . . . . . . . . . . . . . .
Licensing legal settlement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on sale of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of fixed assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Arbitration award and related costs . . . . . . . . . . . . . . . . . . . . . . .
Acquisition integration expenses . . . . . . . . . . . . . . . . . . . . . . . .

Total costs and expenses . . . . . . . . . . . . . . . . . . . . . . . . . . .

Income from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other income (expense):

Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-down of investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Debt extinguishment and refinancing . . . . . . . . . . . . . . . . . . . . .
Write-down of note receivable with former joint venture . . . . .
3CI legal settlement (2005)/proceeds from insurance

(2006 and 2007)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other expense, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

514,846
176,737
—
(2,099)
2,269
1,261
13,904
1,305

708,223

224,544

1,590
(33,965)
(2,930)
—
—

3,300
(1,299)

439,770
144,366
—
—
—
300
—
3,439

587,875

201,762

1,358
(28,419)
(1,000)
—
—

1,025
(2,152)

Total other expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(33,304)

(29,188)

Income before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Earnings per common share:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

191,240
72,862

118,378

1.35

1.32

$

$

$

$

$

$

172,574
67,304

105,270

$

67,154

1.19

1.16

$

$

0.76

0.74

Weighted average number of common shares outstanding:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

87,578,650
89,933,242

88,466,990
90,529,998

88,569,160
90,621,018

The accompanying notes are an integral part of these financial statements.

32

STERICYCLE, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
In thousands

Years Ended December 31,
2006

2005

2007

OPERATING ACTIVITIES:
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adjustments to reconcile net income to net cash provided by operating activities:

Gain on sale of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on sale and impairment of fixed assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of intangibles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write down of investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-off a deferred financing costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-down of note receivable with former joint venture . . . . . . . . . . . . . . . . . . . . .
Stock compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Excess tax benefit of disqualifying dispositions of stock options and exercise of

non-qualified stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 118,378

$ 105,270

$ 67,154

(2,099)
1,261
2,269
2,930
—
—
10,714

(8,054)
27,480
3,657
17,265

(11,400)
6,987
1,566
537
2,551

—
300
—
1,000
—
—
10,610

(8,427)
24,070
2,966
12,937

(14,742)
(6,003)
28,107
280
3,794

—
872
1,431
—
447
2,495
27

7,432
19,835
1,596
13,514

(19,679)
7,393
(8,056)
2,737
(2,871)

Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

174,042

160,162

94,327

INVESTING ACTIVITIES:

Payments for acquisitions and international investments, net of cash acquired . . . .
Proceeds from maturity/(purchase) of short-term investments . . . . . . . . . . . . . . . . .
Proceeds from sale of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from sale of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Capital expenditures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(114,781)
1,301
26,616
—
(48,397)

(164,015)
(1,828)
—
832
(36,414)

(139,696)
(621)
10,328
302
(26,314)

Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(135,261)

(201,425)

(156,001)

FINANCING ACTIVITIES:

Proceeds from issuance of note payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repayment of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Borrowings on senior credit facility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repayments of senior credit facility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Principal payments on capital lease obligations . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payments of deferred financing costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchase/ cancellation of treasury stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from other issuance of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Excess tax benefit of stock options exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net cash (used in)/ provided by financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Effect of exchange rate changes on cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net decrease in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash and cash equivalents at beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—
(30,447)
506,472
(428,786)
(212)
(606)
(103,679)
16,569
8,054

(32,635)
(2,530)

3,616
13,492

5,953
(30,735)
362,452
(265,988)
(816)
(453)
(42,757)
16,464
8,427

52,547
(5,617)

5,667
7,825

735
(12,845)
399,022
(278,706)
(795)
(1,484)
(60,657)
14,230
—

59,500
2,149

(25)
7,850

Cash and cash equivalents at end of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 17,108

$ 13,492

$

7,825

NON-CASH ACTIVITIES:

Net issuance of notes payable for certain acquisitions . . . . . . . . . . . . . . . . . . . . . . .
Net issuance of common stock for certain acquisitions . . . . . . . . . . . . . . . . . . . . . .

$ 112,509
13,667

$ 30,157
750

$ 49,736

—

The accompanying notes are an integral part of these financial statements.

33

STERICYCLE, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Years Ended December 31, 2007, 2006 and 2005
In thousands

Issued and
Outstanding
Shares

Amount

Additional
Paid-In
Capital

Retained
Earnings

Accumulated
Other
Comprehensive
Income (Loss)

Total
Equity

Balance at December 31, 2004 . . . . . . . . . . . . . . . .

89,464

$896

$ 297,598 $194,417

$ 2,461

$ 495,372

Issuance of common stock for exercise of options

and warrants and employee stock purchases . . . .
Purchase/Cancellation of treasury stock . . . . . . . . .
Excess tax benefit of disqualifying dispositions of
stock options and exercise of non-qualified
stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Currency translation adjustment . . . . . . . . . . . . . . .
Change in fair value of cashflow hedge . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Comprehensive income . . . . . . . . . . . . . . . . . . . . . .

1,336
(2,500)

14
(26)

14,234
(60,631)

—

—
—
—

—

—
—
—

7,432

—
—
—

—
—

—

—
—

—

—
—
67,154

(1,817)
(98)
—

14,248
(60,657)

7,432

(1,817)
(98)
67,154

65,239

Balance at December 31, 2005 . . . . . . . . . . . . . . . .

88,300

$884

$ 258,633 $261,571

$

546

$ 521,634

Balance at December 31, 2006 . . . . . . . . . . . . . . . .

88,504

$886

$ 252,125 $366,841

$ 5,229

$ 625,081

Issuance of common stock for exercise of options

and warrants and employee stock purchases . . . .
Purchase/ Cancellation of treasury stock . . . . . . . .
Stock compensation expense . . . . . . . . . . . . . . . . .
Excess tax benefit of disqualifying dispositions of
stock options and exercise of non-qualified
stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Currency translation adjustment . . . . . . . . . . . . . . .
Change in fair value of cashflow hedge . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Comprehensive income . . . . . . . . . . . . . . . . . . . . . .

Issuance of common stock for exercise of options

and warrants and employee stock purchases . . . .
Issuance of common stock for acquisitions . . . . . .
Purchase/ Cancellation of treasury stock . . . . . . . .
Stock compensation expense . . . . . . . . . . . . . . . . .
Excess tax benefit of disqualifying dispositions of
stock options and exercise of non-qualified
stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Currency translation adjustment . . . . . . . . . . . . . . .
Change in fair value of cashflow hedge . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Comprehensive income . . . . . . . . . . . . . . . . . . . . . .

1,540
(1,336)
—

16
(14)
—

17,198
(42,743)
10,610

—

—
—
—

—

—
—
—

8,427

—
—
—
—
— 105,270

4,350
333
—

1,067
228
(2,388)
—

10
2
(24)
—

16,559
13,665
(103,655)
10,714

—

—
—
—

—

—
—
—

8,054

—
—
— 118,378

—
—

25,125
166
—

—
—
—

—

—
—
—

—

—
—
—
—

—

—
—
—
—

—

17,214
(42,757)
10,610

8,427

4,350
333
105,270

109,953

16,569
13,667
(103,679)
10,714

8,054

25,125
166
118,378

143,669

Balance at December 31, 2007 . . . . . . . . . . . . . . . .

87,411

$874

$ 197,462 $485,219

$30,520

$ 714,075

The accompanying notes are an integral part of these financial statements.

34

STERICYCLE, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2007

Unless the context requires otherwise, “we”, “us” or “our” refers to Stericycle, Inc. and its subsidiaries on a

consolidated basis.

Note 1—Description of Business

We were incorporated in 1989 and presently serve approximately 394,600 customers throughout the United
States, United Kingdom, Mexico, Canada, Ireland, Argentina and Puerto Rico. In North America we have a fully
integrated, national network that includes 53 processing centers and 93 additional transfer and collection sites.
We use this network to provide a broad range of services to our customers related to medical waste management
services and regulated return management services. Regulated medical waste management services include
servicing a variety of customers to remove and process waste while regulated return management services are
physical services provided to companies and individual businesses that assist with the handling of products that
are being removed from the supply chain due to recalls and expiration. These services also included advanced
notification technology that is used to communicate specific instructions to the users of the product. Our waste
treatment technologies include autoclaving, incineration, chemical treatment and our proprietary electro-thermal-
deactivation system. In the United Kingdom and Ireland we have a fully integrated network, which includes 19
processing/collection centers and 5 additional transfer/collection sites. In Argentina we own or lease 6 processing
facilities. In addition, we have technology licensing agreements with companies located in Japan, South Africa
and Brazil.

Note 2—Summary of Significant Accounting Policies

Principles of Consolidation:

The consolidated financial statements include the accounts of Stericycle, Inc. and its wholly owned

subsidiaries.

Revenue Recognition:

We recognize revenues for our regulated waste services at the time of waste collection. Payments received
in advance are deferred and recognized as services are provided. Revenues from regulated returns management
services are recorded at the time services are performed. Royalty revenues, which are not material, are calculated
based on measurements specified in each contract or license and revenues are recognized at the end of each
reporting period when the activity being measured has been completed. Revenues from product sales are
recognized at the time the goods are shipped to the ordering customer. Software licensing revenues, which are
not material, are recognized on a prorated basis over the term of the license agreement. We do not have any
contracts in a loss position. Losses would be recorded when known and estimable for any contracts that should
go into a loss position.

Cash Equivalents and Short-Term Investments:

We consider all highly liquid investments with a maturity of less than three months when purchased to
be cash equivalents. Short-term investments consist of certificates of deposit, which mature in less than one
year.

35

Property, Plant and Equipment:

Property, plant and equipment are stated at cost. Depreciation and amortization, which include the
depreciation of assets recorded under capital leases, are computed using the straight-line method over the
estimated useful lives of the assets as follows:

Building and Improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Machinery and Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Containers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Transportation Equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Office Equipment and Furniture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5 to 30 years
3 to 20 years
2 to 20 years
4 to 7 years
3 to 10 years
3 to 7 years

Our containers have a weighted average useful life of 8.9 years.

During the years ended December 31, 2007 and 2006 we wrote down $1.3 million and $0.3 million,
respectively, related to equipment that had been permanently idled. During the year ended December 31, 2005
we recorded a non-cash impairment charge of $0.9 million related to our Springhill, Louisiana building and
property.

Goodwill and Identifiable Intangibles:

Goodwill and identifiable indefinite lived intangibles are not amortized, but are subject to an annual
impairment test according to Statement of Financial Accounting Standards (“SFAS”) No. 142. Other intangible
assets will continue to be amortized over their useful lives. We have determined that our customer relationships
have useful lives from 20 to 40 years based upon the type of customer, with a weighted average useful life of
37.9 years. We have non-compete intangibles with useful lives from one to ten years, with a weighted average
useful life of 4.8 years. We have tradename intangibles with useful lives from 20 to 40 years, with a weighted
average useful life of 38.3 years. We have software technology intangibles with useful lives from three to five
years, with a weighted average useful life of 4.4 years. We have determined that our permits have indefinite lives
and thus they are not amortized.

Valuation of our intangible customer relationships and permits is derived using a discounted income
approach. Financial information such as revenues, costs, assets, and liabilities related to the intangible asset are
input into a standard valuation model to determine a stream of income attributable to that intangible. The income
stream is then discounted to the present to arrive at a valuation. We perform annual impairment tests, in
accordance with SFAS No. 142, on our indefinite lived intangible assets.

Valuation of Intangibles:

Our permits are currently tested for impairment annually at December 31, or more frequently if
circumstances indicate that they may be impaired. We use a discounted income approach model as the current
measurement of the fair value of the permits. The estimate of income is based upon, among other things, certain
assumptions about expected future operating performance and an appropriate discount rate determined by
management. Our estimates of discounted income may differ from actual income due to, among other things,
inaccuracies in economic estimates.

Amortizable identifiable intangible assets, such as customer relationships,

tradenames and covenants
not-to-compete, are currently amortized using the straight-line method over their estimated useful lives. We have
determined that our regulated waste customer relationships have between 20-year and 40-year lives based on the
specific type of relationship. The valuation of our contractual customer relationships was derived using a
testing
discounted income approach valuation model similar to the method used for permit

impairment

36

mentioned earlier. These assets are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may be less than its undiscounted estimated future cash flows. (see
Note 9 to our consolidated financial statements).

Income Taxes:

Deferred income tax liabilities and assets are determined based on the differences between the financial
statement and income tax basis of assets and liabilities using enacted tax rates in effect for the year in which the
differences are expected to reverse.

Accounts Receivable:

Accounts receivable consist primarily of amounts due to us from our normal business activities. We do not
require collateral as part of our standard trade credit policy. Accounts receivable balances are determined to be
past due when the amount is overdue based on the contractual terms with the customer. We maintain an
allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past
collection history and specific risks identified among uncollected accounts. Accounts receivable are written off
against the allowance for doubtful accounts when we have determined that the receivable will not be collected
and/or when the account has been referred to a third party collection agency. Bad debt expense was $4.4 million,
$4.2 million and $2.7 million for the years ended December 31, 2007, 2006 and 2005, respectively.

Financial Instruments:

Our financial instruments consist of cash and cash equivalents, short-term investments, derivatives, accounts
receivable and payable and long-term debt. The fair values of these financial instruments were not materially
different from their carrying values. Financial instruments, which potentially subject us to concentrations of
credit risk, consist principally of accounts receivable. Credit risk on trade receivables is minimized as a result of
the large size of our customer base. No single customer represents greater than 2% of total accounts receivable.
We perform ongoing credit evaluation of our customers and maintain allowances for potential credit losses. For
any contracts in loss positions, losses are recorded when known and estimable. These losses, when incurred, have
been within the range of our expectations. Notes payable are financial liabilities with carrying values that
approximate fair value.

Use of Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles requires
us to make estimates and assumptions that affect
the amounts reported in the financial statements and
accompanying notes. Some areas where we make estimates include allowance for doubtful accounts, credit
memo reserve, accrued employee health and welfare benefits, income tax liabilities and accrued auto and
workers’ compensation insurance claims. Such estimates are based on historical trends and on various other
assumptions that are believed to be reasonable under the circumstances. Actual results could differ from our
estimates.

Derivative Instruments:

We have two forward contracts for the purchase of Sterling (GBP) as hedging instruments for an
intercompany loan from the parent company to our subsidiary in the United Kingdom, Stericycle International
Ltd, which are described more fully in Note 8. The subsidiary borrowed the funds for the purchase of all the
common stock of White Rose Environmental, Ltd. The forward contracts align with the anticipated repayment
schedule of the loan and the last contract expires in July 2009.

Stock-Based Compensation:

In December 2004, the Financial Accounting Standards Board issued SFAS No. 123R, Share-Based
Payment (“SFAS No. 123R”). SFAS No. 123R is a revision of SFAS No. 123, Accounting for Stock-Based

37

Compensation (“SFAS No. 123”), and supersedes Accounting Principles Board Opinion No. 25, Accounting for
Stock Issued to Employees (“APB No. 25”), and its related implementation guidance. No stock based compensation
expense was recognized in 2005 for stock options issued in connection with our stock option plans and through our
Employee Stock Purchase Plan (the “ESPP”) under the “intrinsic value” rules in APB No. 25. On January 1, 2006,
we adopted the provisions of SFAS No. 123R using the modified prospective method to account for stock
compensation costs. SFAS No. 123R requires the measurement and recognition of compensation expense for all
stock-based payment awards made to our employees and directors. Under the fair value recognition provisions of
SFAS No. 123R, stock-based compensation cost is measured at the grant date based on the value of the award and is
recognized as expense over the vesting period. Determining the fair value of stock-based awards at the grant date
requires considerable judgment, including estimating expected volatility, expected term and risk-free rate. Our
expected volatility is based upon historical experience. The expected term of the stock options is based upon the
historical volatility of our stock price. The risk-free interest rate assumption is based upon the U.S. Treasury yield
rates for a comparable period. If factors change and we employ different assumptions, stock-based compensation
expense may differ significantly from what we have recorded in the past.

Foreign Currency Translation:

Assets and liabilities of foreign affiliates that use the local currency as their functional currency are
translated at the exchange rate on the last day of the accounting period, and income statement accounts are
translated at the average rates during the period. Related translation adjustments are reported as a component of
comprehensive income in shareholders’ equity.

Environmental Matters:

We record a liability for environmental remediation or damages when a cleanup program becomes probable
and the costs or damages can be reasonably estimated. We do not have any environmental liabilities recorded at
December 31, 2007 nor are we aware of any issues at our facilities that could initiate the need for environmental
remediation.

Reclassifications:

Certain amounts in the 2006 financial statements have been reclassified to conform to the 2007 presentation.

New Accounting Standards:

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (“SFAS No. 157”). SFAS
No. 157 defines fair value, establishes a framework for measuring fair value in accordance with generally
accepted accounting principles, and expands disclosure about fair value measurements. This statement does not
require any new fair value measurements; rather, it applies to other accounting pronouncements that require or
permit fair value measurements as well as numerous disclosure requirements. SFAS No. 157 is effective for
fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. We do not believe
the adoption of SFAS No. 157 will have a material impact on our financial position, cash flows or results of
operations.

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and
Financial Liabilities—Including an amendment of FASB Statement No. 115” (“SFAS No. 159”). SFAS No. 159
allows measurement at fair value of eligible financial assets and liabilities that are not otherwise measured at fair
value. If the fair value option for an eligible item is elected, unrealized gains and losses for that item are reported
in current earnings at each subsequent reporting date. SFAS No. 159 also establishes presentation and disclosure
requirements designed to draw comparisons between the different measurement attributes that we elect for
similar types of assets and liabilities. SFAS No. 159 is effective for fiscal years beginning after November 15,
2007. We do not believe the adoption of SFAS No. 159 will have a material impact on our financial position,
cash flows or results of operations.

38

In December 2007, the FASB issued Statement of Financial Accounting Standards No. 141 (revised 2007),
“Business Combinations” (“SFAS No. 141(R)”). SFAS No. 141(R) replaces SFAS No. 141, Business
Combinations. SFAS No. 141(R) requires the acquiring entity in a business combination to recognize the full fair
value of assets acquired and liabilities assumed in the transaction; requires certain contingent assets and liabilities
acquired to be recognized at their fair values on the acquisition date; requires contingent consideration to be
recognized at its fair value on the acquisition date and changes in the fair value to be recognized in earnings until
settled; requires the expensing of most transaction and restructuring costs; and generally requires the reversals of
valuation allowances related to acquired deferred tax assets and changes to acquired income tax uncertainties to
also be recognized in earnings. This accounting standard is effective for financial statements issued for fiscal
years beginning after December 15, 2008. We are currently evaluating the provisions of SFAS No. 141(R) to
determine the potential impact, if any, the adoption will have on our financial position and results of operations.

Note 3—Acquisitions and Divestiture

During 2007, we completed 19 acquisitions, of which ten were domestic medical waste businesses, one was
a domestic assembler and distributor of containers that we use in our mail-back program, one was a medical
waste business in Canada, six were medical waste businesses in Latin America, and one was a medical waste
business in Europe. The two largest acquisitions were MedSolutions, Inc. in Texas, and Commodore Medical
Services, L.P. in Tennessee. In addition, we acquired the remaining minority interest of our Medam S.A. de C.V.
subsidiary in Mexico and became the sole owner of our Medam B.A. subsidiary in Argentina, previously
accounted for as a minority interest using the equity method of accounting.

The aggregate net purchase price of all our acquisitions, including adjustments for purchase accounting was
approximately $241.0 million, of which $114.8 million was paid in cash, $112.5 million was paid by the issuance
of promissory notes and $13.7 million was paid by the issuance of shares of our common stock. The purchase
prices of these acquisitions have been primarily allocated to identifiable intangible assets and goodwill, reflecting
the complementary strategic fit that the acquired businesses brought to us.

In February 2007, we sold three incinerators and associated customer contracts in the United Kingdom to
comply with a remedy accepted by United Kingdom Competition Commission, as we reported in our Form 10-K
for 2006. The sales price was $26.5 million and resulted in a gain of approximately $1.9 million. The selected
assets, which included $13.1 million of goodwill, and related liabilities are presented on our balance sheet at
December 31, 2006 as “Assets of disposal group held for sale” and “Liabilities of disposal group held for sale”.

During the year ended December 31, 2006, we completed 16 acquisitions, of which seven were domestic
and nine were international. We completed one acquisition in Canada, six in Mexico, one in Ireland and one in
Argentina. The largest of our acquisitions during the year was The Sterile Technologies Group Limited in Ireland
(“STG”). We acquired all of the stock of STG for approximately $131.0 million, of which $114.0 million was
paid in cash and $17.0 million was paid by the assumption of debt. The aggregate net purchase price of these
acquisitions was approximately $194.9 million, of which approximately $164.0 million was paid in cash, $30.1
million was paid by the issuance of promissory notes and $0.8 million was paid by the issuance of shares of our
common stock.

During the year ended December 31, 2005 we completed 22 acquisitions, of which 13 were domestic and
nine were international. We completed seven acquisitions in Mexico and two in the United Kingdom. NNC
Group, LLC in Indiana and Universal Solution International, Inc. (“USI”) in North Carolina were our two largest
acquisitions during the year. In connection with the USI acquisition, we sold selected assets of USI’s consumer
products division to Carolina Supply Chain Services LLC for $12.3 million, of which $10.3 million was the net
amount received in cash. The aggregate net purchase price of these acquisitions was approximately $189.4
million, of which approximately $139.7 million was paid in cash and $49.7 million was paid by the issuance of
promissory notes.

39

For financial reporting purposes these acquisitions were accounted for using the purchase method of
accounting. The total purchase price for 2007, 2006 and 2005 of $241.0 million, $194.9 million and $189.4
million, respectively, net of cash acquired, was allocated to the assets acquired and liabilities assumed based on
the estimated fair market value at the date of acquisition. In certain cases, the purchase price is or was subject to
downwards adjustment if revenues from customer contracts acquired failed to reach certain specified levels. The
excess of the purchase price over the fair market value of the net assets acquired is reflected in the accompanying
consolidated balance sheets as goodwill. Some allocations are pending completion of certain intangible asset
valuations. Goodwill was recorded in the amounts of $203.8 million, $119.3 million and $170.0 million during
the years 2007, 2006 and 2005, respectively. The results of operations of these acquired businesses have been
included in the consolidated statements of income from the date of the acquisition.

We intend to continue to seek opportunities to acquire businesses that expand our national networks in the
United States and internationally and increase our customer base. We believe that our acquisitions will enable us
to improve our operating efficiencies through increased utilization of our service infrastructure.

Note 4—Property, Plant and Equipment

Property, plant and equipment at December 31 consist of the following items:

Land . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Building and improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Machinery and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Office equipment and furniture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Internally developed software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Construction in progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2007

2006

in thousands

$ 12,879
59,447
207,145
32,913
4,061
16,648

$ 10,582
52,384
173,769
27,342
2,567
11,116

Total property, plant & equipment . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Accumulated depreciation and amortization . . . . . . . . . . . . . . . . . . . . .

333,093
(140,054)

277,760
(120,807)

Property, plant and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . .

$ 193,039

$ 156,953

Note 5—Income Taxes

Significant components of our income tax expense for the years ended December 31, 2007, 2006 and 2005

are as follows:

Current

2007

2006
in thousands

2005

U.S. federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$39,440
8,042
3,298

$40,764
7,857
5,235

$23,530
4,561
2,819

Deferred

U.S. federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$14,275
2,805
5,002

$ 9,131
2,534
1,783

$10,720
2,730
466

50,780

53,856

30,910

Total provision . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$72,862

$67,304

$44,826

22,082

13,448

13,916

40

A reconciliation of the income tax provision computed at the federal statutory rate to the effective tax rate

for the years ended December 31, 2007, 2006 and 2005 are as follows:

Federal statutory income tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Effect of:

State taxes, net of federal tax effect

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Effective tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2007

2006

2005

35.0% 35.0% 35.0%

3.7% 3.9%
4.1%
(0.6%)
0.9%
0.1%
38.1% 39.0% 40.0%

Cash payments for income taxes were $45.9 million, $30.1 million and $28.1 million for the years ended

December 31, 2007, 2006 and 2005, respectively.

Our deferred tax liabilities and assets as of December 31, 2007 and 2006 are as follows:

2007

2006

in thousands

Deferred tax liabilities:

Property, plant and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill and other intangibles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (20,265) $ (12,963)
(104,776)
(91,641)
(917)

—

Total deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(125,041)

(105,521)

Deferred tax assets:

Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net operating tax loss carryforward . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9,146
2,930
1,434

9,545
2,077
4,450

Total deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

13,510

16,072
$(111,531) $ (89,449)

At December 31, 2007, net operating loss carry forwards for U.S. federal and state income tax purposes have been
fully utilized, excluding net operating loss carry forwards related to our subsidiary, 3CI Complete Compliance
Corporation (“3CI”). Stericycle acquired 3CI’s net operating loss carry forwards during 2006 and as a result has a
remaining net operating loss carry forward for federal and state purposes of $4.1 million which began to expire in 2006.

We have a foreign tax credit of approximately $0.1 million, which will begin to expire beginning in 2010.
Undistributed earnings of foreign subsidiaries are considered permanently invested, and therefore no U.S.
deferred taxes are recorded thereon. The cumulative amounts of such earnings are $43.4 million at December 31,
2007, and it was not practicable to estimate the U.S. withholding tax thereon assuming repatriation.

In September 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48,
“Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109” (“FIN 48”). This
interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial
statements in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 109, “Accounting for
Income Taxes”. This Interpretation prescribes a recognition threshold and measurement attribute for the financial
statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. This
interpretation also provides guidance on de-recognition, classification, interest and penalties, accounting in interim
periods, disclosure and transition. We adopted the provisions of FIN 48 on January 1, 2007. The adoption of FIN 48
did not have a material impact on our consolidated financial statements.

We and our subsidiaries file U.S. federal income tax returns and income tax returns in various states and
foreign jurisdictions. With a few exceptions, we are no longer subject to U.S. federal, state, local, or non-U.S.

41

income tax examinations by tax authorities for years before 2001. In the third quarter of 2006 the Internal
Revenue Service (“IRS”) began an examination of the Company’s U.S. income tax return for 2004. This
examination was settled in the second quarter of 2007, and we paid an immaterial amount during the third quarter
of 2007 for additional tax and interest with respect to adjustments to our deduction for state income tax expense
and currency losses. Tax years 2005 and 2006 remain open and subject to examination by the IRS, and our
subsidiaries in foreign countries have tax years open ranging from 2002 through 2006.

The total amount of unrecognized tax benefit reserve as of December 31, 2007 is $3.7 million, which
includes immaterial amounts of interest and penalties and is reflected as a liability on the balance sheet. The
amount of income tax contingency reserve that, if recognized, would affect the effective tax rate is approximately
$3.7 million. At December 31, 2007, the balances have not materially changed nor do we expect a significant
increase or decrease to these balances over the next twelve months. We recognize interest and penalties accrued
related to income tax reserves in income tax expense. This method of accounting is consistent with prior years.

The following table shows reconciliation of income tax reserves as of December 31, 2007:

Unrecognized tax benefit reserve, January 1, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross increases- tax positions in prior period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross decreases- tax positions in prior period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross increase- current period tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Settlement
Lapse of statute of limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Unrecognized tax benefit reserve, December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . .

in thousands

$4,400
1,228
(188)
—
(925)
(840)

$3,675

Note 6—Long-Term Debt

Long-term debt consists of the following at December 31:

Obligations under capital leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Senior credit facility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Notes payable and other foreign debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Less: Current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2007

2006

in thousands

$

1,709
465,434
168,641

635,784
22,003

$

617
387,265
77,914

456,796
22,681

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$613,781

$443,115

Payments due on long-term debt, excluding capital

lease obligations, during each of the five years

subsequent to December 31, 2007 are as follows:

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

in thousands

$ 21,410
19,067
26,374
13,547
486,673
67,004

$634,075

We paid interest of $31.8 million, $27.6 million and $13.5 million for the years ended December 31, 2007,

2006 and 2005, respectively.

42

Property under capital

leases included with property, plant and equipment

in the accompanying

Consolidated Balance Sheets is as follows at December 31:

2007

2006

Buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Machinery and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Office equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vehicles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Accumulated depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . .

$

$ —

in thousands
138
456
62
2,227
(1,198)

142
—
6,123
(5,853)

$ 1,685

$

412

Amortization related to these capital leases is included with depreciation expense.

Minimum future lease payments under capital leases are as follows:

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total minimum lease payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less amounts representing interest

Present value of net minimum lease payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

in thousands

$ 683
570
420
195
7

1,875
(166)

1,709
(593)

Long-term obligations under capital leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,116

Senior Credit Facility

In August 2007, we entered into a new credit agreement. The new credit agreement was in substance an
amendment of our existing credit agreement. The amended credit facility reduces the interest rates that we are
charged by reducing the applicable margin that is added to the relevant interest rate. Our borrowings bear interest
at fluctuating interest rates determined, at our election in advance for any quarterly or other applicable interest
period, by reference to (i) a “base rate” (the higher of the prime rate at Bank of America, N.A. or 0.5% above the
rate on overnight federal funds transactions) or (ii) the London Interbank Offered Rate, or LIBOR, plus, in either
case, the applicable margin within the relevant range of margins provided in our credit agreement. The applicable
margin is based upon our consolidated leverage ratio. As of December 31, 2007, the margin for interest rates on
borrowings under our new credit facility was 0.0% on base rate loans and 0.625% on LIBOR loans. In addition to
the change in applicable margin, the facility was increased from $650 million to $850 million, with an additional
capacity available up to $200 million upon request. We also increased both the letter of credit sublimit and
alternative currency sublimit to $300 million from $200 million each. The maturity date was extended from July
2011 to August 2012.

As of December 31, 2007, we had $465.4 million of borrowings outstanding under our senior unsecured
credit facility, which includes foreign currency borrowings of $16.0 million. In addition, we had $139.4 million
committed to outstanding letters of credit. As of December 31, 2007 the weighted average rate of interest on the
unsecured revolving credit facility was 5.53% per annum.

In July 2006 we, and certain of our subsidiaries, entered into a credit agreement with Bank of America,
N.A., and other lenders party to the credit agreement. The credit agreement was in effect an amendment of our
then existing senior unsecured credit facility.

43

The 2006 credit agreement (i) reduced our costs of borrowing by using a more favorable pricing grid;
(ii) increased our revolving credit facility from $550 million to $650 million; (iii) increased the “accordion” (the
amount for which we could request an increase in the size of our revolving credit facility) from $100 million to
$200 million; (iv) increased the letter of credit sublimit from $150 million to $200 million; (v) increased the
foreign currency sublimit from $125 million to $200 million; (vi) increased the debt-to-EBITDA covenant from
3.00:1.00 to 3.75:1.00; and (vii) extended the maturity date of our borrowings from June 30, 2010 to July 31,
2011.

As of December 31, 2006, we had $387.3 million of borrowings outstanding under our senior unsecured
credit facility, which includes foreign currency borrowings of $9.3 million. In addition, we had $48.8 million
committed to outstanding letters of credit. As of December 31, 2006 the weighted average rate of interest on the
unsecured revolving credit facility was 6.08% per annum.

Notes Payable and Foreign Subsidiary Debt

At December 31, 2007 we had promissory notes and foreign subsidiary bank debt, primarily issued as a
result of acquisitions, totaling $168.6 million. Of the $168.6 million, $139.4 million of promissory notes was
secured with letters of credit. Of the $168.6 million, $138.6 million had a fixed interest rate and $30.0 million
had a floating interest rate. The weighted average interest rate was 5.79%, and the weighted average maturity was
approximately 5.9 years.

At December 31, 2006 we had promissory notes and foreign subsidiary bank debt, primarily issued as a
result of acquisitions, totaling $77.9 million. Of the $77.9 million, $48.8 million of promissory notes was secured
with letters of credit. Of the $77.9 million, $49.1 million had a fixed interest rate and $28.8 million had a floating
interest
rate was 6.21%, and the weighted average maturity was
approximately 4.4 years.

rate. The weighted average interest

Guarantees

We have guaranteed a loan to JPMorganChase Bank N.A. on behalf of Shiraishi-Sogyo Co. Ltd
(“Shiraishi”). Shiraishi is a customer in Japan that is expanding their medical waste management business and
has a six month loan with JPMorganChase Bank N.A. with a current balance of $4.3 million. This loan expires in
May 2008. Management currently believes no amount will be paid under the guarantee.

Note 7—Accrued Liabilities

Accrued liabilities at December 31 consist of the following items:

Accrued compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued insurance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued income tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued professional liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities- other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2007

2006

in thousands

$16,898
16,770
11,446
3,214
5,489
21,754

$13,507
15,214
18,328
1,840
2,503
24,042

Total accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$75,571

$75,434

Note 8—Derivative Instruments

In July 2004, we entered into four forward contracts, of which two have settled, to hedge a GBP Sterling-
based intercompany loan between our US-based subsidiary, Stericycle International L.L.C. and our subsidiary in
the United Kingdom, Stericycle International Ltd. The subsidiary borrowed the funds for the purchase of White

44

Rose. The forward contracts align with the anticipated repayment schedule of the loan and the last contract
expires in July 2009. Initially, we did not elect hedge accounting on the forward contracts and had recognized the
change in value of the hedges through other income (expense). This amount was generally offset by the currency
adjustment to the intercompany receivable.

On October 1, 2005, we prospectively designated these existing forward contracts as cash flow hedges and
are using hedge accounting. The objective of our cash flow hedges is to offset the foreign exchange risk to the
U.S. dollar equivalent cash inflows on the settlement of the GBP denominated intercompany loan. During 2007
and 2006 the cost of the forward contracts recognized was immaterial to our net income. At December 31, 2007,
the fair market value of the hedge was recorded as a liability of $2.6 million of which $0.7 million is current. As
of December 31, 2007, the total notional amount of hedges outstanding is GBP 11.0 million. At December 31,
2007 the hedges were determined to be 100% effective.

Note 9—Goodwill and Other Intangible Assets

Under SFAS No. 142, “Goodwill and Other Intangible Assets”, goodwill and other indefinite lived
intangibles are no longer amortized and are subject to an annual impairment test, or to more frequent testing if
circumstances indicate that they may be impaired.

We have two geographical reporting segments, “United States” and “Foreign Countries”, both of which
have goodwill. The changes in the carrying amount of goodwill for the years ended December 31, 2007 and 2006
was as follows:

United
States

Foreign
Countries

Total

Balance as of December 31, 2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill acquired during year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes due to currency fluctuation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$621,496
26,028
—

in thousands
$ 63,673
93,311
9,465

$ 685,169
119,339
9,465

Balance as of December 31, 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill acquired during year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes due to currency fluctuation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

647,524
195,454
—

166,449
8,362
15,544

813,973
203,816
15,544

Balance as of December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$842,978

$190,355

$1,033,333

During the quarter ended June 30, 2007 we performed our annual goodwill impairment evaluation for our three
operating units, Domestic Regulated Medical Waste, Domestic Regulated Returns Management and Foreign
Countries, and determined that none of our recorded goodwill was impaired. We complete our annual impairment
analysis of our indefinite lived intangibles (facility permits) during the quarter ended December 31 of each year.

In 2007 we wrote off $2.0 million for the White Rose Environmental tradename as a result of the name
change of our subsidiary in the United Kingdom, and we wrote off $0.2 million for the permit intangible for a
treatment facility in the United Kingdom that was no longer being used. These intangibles were part of the
Foreign Countries segment and the write off is reported in our Statement of Income as impairment of intangible
assets. In 2007 and 2006 we performed our annual permit impairment evaluation and determined that, other than
noted above, there was no impairment. At December 31, 2007 and 2006, we had $52.8 million and $32.2 million,
respectively, of indefinite lived intangibles that consist of environmental permits for which we performed an
annual impairment test, and determined there was no impairment.

According to SFAS 142, other intangible assets will continue to be amortized over their useful lives.

In 2007, we assigned $15.9 million to customer relationships with amortization periods of 20 to 40 years,
$16.7 million to facility environmental permits with indefinite lives, $2.5 million to non-compete agreements
with amortization periods of one to ten years, and $0.1 million to proprietary technology with an amortization
periods of three to five years.

45

In 2006, we assigned $41.2 million to customer relationships with amortization periods of 20 to 40 years,
$13.6 million to facility environmental permits with indefinite lives, $0.3 million to non-compete agreements
with amortization periods of one to five years, and $0.2 million to proprietary technology with an amortization
period of three years.

As of December 31, the value of the amortizing intangible assets were as follows:

Gross
Carrying Amount

Accumulated
Amortization

Net
Carrying Amounts

2007

2006

2007

2006

2007

2006

in thousands

Non-compete . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Customer relationships . . . . . . . . . . . . . . . . . . . .
Tradenames . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
License agreements . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

4,423
103,249
1,200
2,779
441

$ 7,184
83,330
3,754
500
341

$ 1,825
7,349
156
2,687
213

$ 6,357
4,355
297
308
137

$ 2,598
95,900
1,044
92
228

$

827
78,975
3,457
192
204

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$112,092

$95,109

$12,230

$11,454

$99,862

$83,655

During the years ended December 31, 2007, 2006 and 2005 the aggregate amortization expense was $3.7

million, $3.0 million and $1.6 million, respectively.

The estimated amortization expense for each of the next five years is as follows for the years ended

December 31:

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

In thousands

$3,843
3,635
3,474
3,002
2,958

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates

for amortization expense noted above are based upon foreign exchange rates as of December 31, 2007.

Note 10—Lease Commitments

We lease various plant equipment, office furniture and equipment, motor vehicles and office and warehouse
space under operating lease agreements, which expire at various dates over the next 12 years. The leases for most
of the properties contain renewal provisions.

Rent expense for 2007, 2006 and 2005 was $32.4 million, $28.7 million and $25.8 million, respectively.

Minimum future rental payments under non-cancelable operating leases that have initial or remaining terms
in excess of one year as of December 31, 2007 for each of the next five years and in the aggregate are as follows:

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2011 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

In thousands

$ 31,083
27,574
22,634
17,123
11,429
28,725

$138,568

46

Note 11—Net Income Per Common Share

During the quarter ended June 30, 2007 our shareholders approved the increase in our authorized shares of
common stock from 80,000,000 shares to 120,000,000 shares. In addition, the Board of Directors authorized a
2-for-1 stock split. The stock split was in the form of a stock dividend of one share payable on May 31, 2007 in
respect of each share of common stock outstanding on the record date of May 17, 2007. Historic share and per
share amounts have been adjusted to reflect the stock split.

The following table sets forth the computation of basic and diluted net income per share:

Years Ended December 31,

2007

2006

2005

In thousands, except share and per share data

Numerator:
Numerator for basic earnings per share

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

118,378

$

105,270

$

67,154

Denominator:
Denominator for basic earnings per share-weighted average

shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

87,578,650

88,466,990

88,569,160

Effect of diluted securities:

Employee stock options . . . . . . . . . . . . . . . . . . . . . . . . . . .
Warrants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,348,589
6,003

2,062,444
564

2,051,644
214

Dilutive potential shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,354,592

2,063,008

2,051,858

Denominator for diluted earnings per share-adjusted weighted

average shares and after assumed exercises . . . . . . . . . . . . . . . . . .

89,933,242

90,529,998

90,621,018

Earnings per share—Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Earnings per share—Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

1.35

1.32

$

$

1.19

1.16

$

$

0.76

0.74

For additional information regarding outstanding employee stock options and outstanding warrants, see

Note 12.

In 2007, 2006 and 2005, options and warrants to purchase 279,081 shares, 1,565,864 shares and 66,416
shares, respectively, at exercise prices of $38.57-$59.70, $17.53-$36.26 and $22.11-$31.11, respectively, were
not included in the computation of diluted earnings per share (“EPS”) because the effect would be antidilutive.

Note 12—Stock Based Compensation

Share and per share data have been adjusted to reflect 2-for-1 stock split effective May 31, 2007.

Stock Plans:

We have adopted five stock option plans:

(i)

the 2005 Incentive Stock Plan, which our stockholders approved in April 2005;

(ii)

the 2000 Nonstatutory Stock Option Plan, which our Board of Directors adopted in February 2000;

(iii) the 1997 Stock Option Plan, which expired in January 2007;

(iv) the Directors Stock Option Plan, which expired in May 2006;

(v)

the 1995 Incentive Compensation Plan, which expired in July 2005.

The 2005 Plan authorizes awards of stock options and stock appreciation rights for a total of 4,800,000
shares; as amended, the 2000 Plan authorizes stock option grants for a total of 7,000,000 shares; the 1997 and
1995 Plans each authorized stock option grants for a total of 6,000,000 shares; and as amended, the Directors
Plan authorized stock option grants for a total of 2,340,000 shares.

47

The 2005 Plan provides for the grant of nonstatutory stock options (“NSOs”) and incentive stock options
intended to qualify under section 422 of the Internal Revenue Code (“ISOs”) as well as stock appreciation rights;
the 2000 Plan provides for the grant of NSOs; the 1997 and 1995 Plans each provided for the grant of NSOs and
ISOs; and the Directors Plan provided for the grant of NSOs.

The 2005 Plan authorizes awards to our officers, employees and consultants and, following the expiration of
the Directors Plan in May 2006, to our directors; the 2000 Plan authorizes stock option grants to our employees
and consultants, but not to our officers and directors; the 1997 and 1995 Plans each authorized stock option
grants to our officers, directors, employees and consultants; and the Directors Plan authorized stock option grants
to our outside directors.

As of December 31, 2007, we reserved the following shares for issuance, consisting of both shares available
for option grants under the 2005 Plan, 2000 Plan, 1997 Plan and shares granted as options under all five of our
plans, but not yet exercised:

1995 Plan options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1996 Directors Plan options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1997 Plan options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2000 Plan options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2005 Plan options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Warrants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

491,616
474,576
1,292,854
2,904,753
4,750,841
22,000

Total shares reserved . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9,936,640

Employee Stock Purchase Plan:

In October 2000, our Board of Directors adopted the ESPP effective as of July 1, 2001. Our stockholders
approved the ESPP in May 2001. The ESPP authorizes 600,000 shares of our common stock to be purchased by
employees at a 15% discount from the market price of the stock through payroll deductions during two six-month
offerings each year. An employee who elects to participate in an offering is granted an option on the first day of
the offering for a number of shares equal to the employee’s payroll deductions under the ESPP during the
offering period (which may not exceed $5,000) divided by the option price per share. The option price per share
is the lower of 85% of the closing price of a share of our common stock on the first trading day of the offering
period or 85% of the closing price on the last trading day of the offering period. We recognize compensation
expense for the ESPP, which is reflected in the statement of income. Every employee who has completed one
year’s employment as of the first day of an offering and who is a full-time employee, or a part-time employee
who customarily works at least 20 hours per week, is eligible to participate in the offering. During 2007, 2006
and 2005, 43,777 shares, 40,996 shares and 37,144 shares, respectively, were issued through the ESPP.

Stock Based Compensation Expense:

As a result of adopting SFAS No. 123R, our net income was $6.6 million and $6.5 million less for 2007 and
2006, respectively, than if we had continued to account for stock-based compensation under APB No. 25 and its
related interpretations. Basic and diluted net income per share during the years ended December 31, 2007 and
2006 of $1.35 and $1.32, and $1.19 and $1.16, respectively, were negatively impacted by $0.08 and $0.07, and
$0.07 and $0.07, respectively, due to the adoption of SFAS No. 123R.

We have elected to use the modified prospective transition method as permitted by SFAS No. 123R and,
therefore, financial results for prior periods have not been restated. Under this transition method, stock-based
compensation expense for 2006 includes expense for all equity awards granted prior to, but not yet vested as of
January 1, 2006. This compensation expense was based on the grant-date fair value estimated in accordance with
the original provisions of SFAS No. 123 as amended by SFAS No. 148, “Accounting for Stock-Based
Compensation-Transition and Disclosure.” Since the adoption of SFAS No. 123R, there have been no changes to

48

our stock compensation plans or modifications to outstanding stock-based awards which would change the value
of any awards outstanding. Compensation expense for all stock-based compensation awards granted subsequent
to January 1, 2006 was based on the grant-date fair value determined in accordance with the provisions of SFAS
No. 123R. During the years ended December 31, 2007 and 2006, we recognized compensation expense of $10.3
million and $10.3 million, respectively, for stock options, and $0.4 million and $0.3 million, respectively, for the
ESPP, which is reflected in the statement of income. There were no significant capitalized stock-based
compensation costs at December 31, 2007 and 2006.

Prior to January 1, 2006, we accounted for stock-based compensation in accordance with APB No. 25 and
followed the disclosure requirements of SFAS No. 123. Under APB No. 25, we accounted for stock-based
awards to employees and directors using the intrinsic value method as allowed under SFAS No. 123. Under the
intrinsic value method, no stock-based compensation expense was recognized in our statement of income because
the exercise price of the stock options granted to employees and directors equaled the fair market value of the
underlying stock at the date of grant. Options granted were valued using the Black-Scholes option-pricing model
for SFAS No. 123 purposes as well as the following pro forma disclosure assuming the SFAS No. 123 fair value
method was used.

The following table sets forth the computation of basic and diluted loss per share and illustrates the effect on
net income and net income per share as if we had applied the fair value recognition provisions of SFAS No. 123
to our stock-based compensation plan in 2005:

Year Ended
December 31,

2005

in thousands, except
per share data

Stock options expense included in net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

16

As reported net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pro forma impact of stock options, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pro forma impact of employee stock plan, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

67,154
(5,940)
(127)

Pro forma net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$61,087

Earnings per share:

Basic—as reported . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Basic—pro forma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diluted—as reported . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diluted—pro forma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

$

$

0.76

0.69

0.74

0.68

The following table presents the total stock-based compensation expense resulting from stock option awards

and the ESPP included in the consolidated statements of income:

Years Ended
December 31,

2007

2006

Cost of revenues—stock option plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative—stock option plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative—employee stock purchase plan . . . . . . . . . . . . . . . . . . . .

$

$

in thousands
477
9,818
419

784
9,521
305

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$10,714

$10,610

49

As of December 31, 2007, there were $20.3 million of total unrecognized compensation expense, related to

non-vested option awards, which is expected to be recognized over a weighted-average period of 1.68 years.

The following table sets forth the tax benefits related to stock compensation:

Years Ended
December 31,

2007

2006

in thousands

Tax benefit recognized in income statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Excess tax benefit realized . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$4,207
8,054

$3,804
8,427

Stock Options:

Options granted to officers and employees generally vest over five years. During 2007, 2006 and 2005,
options granted to officers and employees generally vested at the rate of 20% of the option shares on each of the
first five anniversaries of the option grant date. Expense related to the graded vesting options is recognized using
the straight-line method over the vesting period.

The exercise price per share of an option granted under any of our stock option plans may not be less than
the closing price of a share of our common stock on the date of grant. The maximum term of an option granted
under any plan may not exceed 10 years. An option may be exercised only when it is vested and, in the case of an
option granted to an employee (including an officer), only while he or she remains an employee and for a limited
period following the termination of his or her employment. New shares are issued upon exercise of stock options.
Option activity for the years ended December 31, 2007, 2006 and 2005 is summarized as follows:

2007

2006

2005

Weighted
average
exercise
price
per share

$20.96
40.24
14.86
29.78
26.68

Number of
options

7,037,310
1,472,403
(1,013,290)
(232,533)
(5,095)

Weighted
average
exercise
price
per share

$16.62
30.46
10.48
24.57
9.24

Weighted
average
exercise
price
per share

$13.57
24.22
10.60
19.90
21.10

Number of
options

6,840,596
1,795,374
(1,292,070)
(154,636)
(3,566)

Number of
options

7,185,698
1,744,536
(1,513,216)
(370,100)
(9,608)

Outstanding at beginning of year . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercised . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . .
Cancelled or expired . . . . . . . . . . . . . . .

Outstanding at end of year . . . . . . . . . . .

7,258,795

$25.44

7,037,310

$20.96

7,185,698

$16.62

. . . . . . . . . . .
Exercisable at end of year
Available for future grant . . . . . . . . . . . .

3,526,237
2,655,845

$18.62

3,348,190
3,899,020

$15.39

3,680,026
5,863,056

$11.96

The total intrinsic value of options exercised for the years ended December 31, 2007 and 2006 was $34.6
million and $34.0 million, respectively. The total intrinsic value represents the total pre-tax intrinsic value (the
difference between our closing stock price on the last day of trading for the year ended December 31, 2007 and
the exercise price, multiplied by the number of in-the-money options) that would have been received by the
option holders assuming all option holders had exercised their options on December 31, 2007; this amount
changes based on the fair market value of our stock.

Outstanding options at December 31, 2007 and 2006 had a weighted average remaining contractual life of
6.8 years and 7.0 years, respectively, with an aggregate intrinsic value of $246.5 million and $118.1 million,
respectively. Exercisable options at December 31, 2007 and 2006 had a weighted average remaining contractual
life of 5.4 years and 5.6 years, respectively, with an aggregate intrinsic value of $143.8 million and $74.9
million, respectively.

50

Options outstanding and exercisable as of December 31, 2007 by price range are presented below:

Options Outstanding

Options Exercisable

Range of Exercise Price

$ 3.188-$13.685 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$15.350-$17.715 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$17.895-$20.500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$20.900-$22.110 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$22.400-$22.700 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$22.775-$22.900 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$22.925-$28.750 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$28.795-$29.540 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$29.590-$38.500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$38.565-$59.700 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Shares

1,074,883
734,253
155,739
806,264
102,495
1,008,243
275,421
1,046,549
661,479
1,393,469

7,258,795

3.26
5.04
4.99
6.12
6.83
7.12
6.82
8.08
8.35
9.19

6.82

Outstanding
Average
Remaining
Life in
Years

Weighted
Average
Exercise
Price

Weighted
Average
Exercise
Price

$ 9.60
17.47
19.33
22.09
22.66
22.90
24.14
29.54
31.96
38.89

Shares

1,074,883
690,568
143,508
557,417
53,190
349,280
228,507
195,705
200,519
32,660

$ 9.60
17.47
19.36
22.08
22.66
22.90
24.35
29.53
32.38
40.35

$25.44

3,526,237

$18.62

The Black-Scholes option-pricing model was used in determining the fair value of each option grant. The
expected term of options granted is based on historical experience. Expected volatility is based upon historical
volatility. The expected dividend yield is zero. The risk-free interest rate is based upon the U.S. Treasury yield
rates of a comparable period. The assumptions that we used in the Black-Scholes model are as follows:

Stock options granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted average grant date fair value . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected term (in years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Risk free interest rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

1,472,403
11.43
5.25
27.07%
0.00%
4.52%

$

1,744,536
8.91
4.5
28.87%
0.00%
4.83%

$

1,795,374
7.26
4.3
32.00%
0.00%
4.05%

Years Ended December 31,

2007

2006

2005

Note 13—Preferred Stock and Warrants

Preferred Stock:

At December 31, 2007 and 2006 we had 1,000,000 authorized shares of preferred stock and no shares issued

or outstanding.

Warrants:

Share and per share data have been adjusted to reflect 2-for-1 stock split effective May 31, 2007.

In September 2003, in connection with an acquisition, we issued warrants to purchase 2,000 shares of our
common stock. The warrants will become exercisable in September 2008. The exercise price of the warrants is
$23.63 per share. At December 31, 2007 all of the warrants were outstanding.

In October 2006, in connection with an acquisition, we issued warrants to purchase 20,000 shares of our
common stock. The exercise price of the warrants is $35.33 per share. At December 31, 2007 all of the warrants
were outstanding and exercisable.

51

Note 14—Employee Benefit plan

We have a 401(k) defined contribution retirement savings plan covering substantially all employees. Each
participant may elect to defer a portion of his or her compensation subject to certain limitations. We may
contribute up to 50% of the first 5% of compensation contributed to the plan by each employee up to a maximum
of $1,500 per annum. Our contributions for the years ended December 31 2007, 2006 and 2005 were
approximately $1.6 million, $1.5 million and $1.3 million, respectively.

Note 15—Non-consolidating Joint Ventures

In 2007 we became the 100% owner of the former joint venture, Medam, B.A. Srl, an Argentine
corporation. As part of a legal restructuring of the business operations of Medam, B.A. we recognized a $2.9
million charge related to the impairment of that investment and write-off of an intercompany loan. In 2006 and
2005, we recorded $0.5 million and $0.3 million, respectively, of equity losses related to the above joint venture,
which were recorded in the other income (expense).

In 2005 we wrote-off a $2.5 million note receivable related to the sale of our minority interest investment in

Evertrade Regulated Waste (Pty) Ltd, a South African company.

Note 16—Legal Proceedings

We operate in a highly regulated industry and must deal with regulatory inquiries or investigations from
time to time that may be instituted for a variety of reasons. We are also involved in a variety of civil litigation
from time to time.

In November 2007, the arbitrator issued a final award in arbitration proceedings in Australia with SteriCorp
Limited. The arbitrator awarded Stericycle $8.2 million USD on our claim against SteriCorp for payments due
under certain convertible notes and awarded SteriCorp $14.5 million USD on its claim that we failed to supply
SteriCorp with equipment conforming to specifications under an equipment supply agreement. The final award
also requires us to pay two-thirds of SteriCorp’s arbitration costs. An estimate of these amounts has been made
and accrued for in our consolidated financial statements. The net effect of the various components of the final
arbitration award was a charge of $13.9 million to our income statement identified as “Arbitration award and
related costs.”

A United Kingdom subsidiary of ours is currently involved in arbitration proceedings with Daniels
Corporation (UK) Limited over White Rose Sharpsmart Limited, a joint venture in which our subsidiary has a
50% interest. We do not believe that these proceedings are material.

Note 17—Products and Services and Geographic Information

SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information,” requires segment
to internally assess
information to be reported based on information utilized by executive management
performance and make operating decisions. We have determined that we have three operating segments based on
the organizational structure of our company and information reviewed. These operating segments are Foreign
Medical Waste Management Services (“Foreign Countries”), Domestic Medical Waste Management Services
(“United States”) and Domestic Returns Management Services. We have aggregated Domestic Medical Waste
Management Services and Domestic Returns Management Services into one reportable segment, United States,
based on our consideration of the following aggregation criteria:

•

•

•

they have similar economic characteristics,

the same services are provided,

the same types of customers are serviced,

52

•

•

•

the same types of waste collection, transportation and treatment methods are utilized,

their regulatory environments are similar, but vary based upon country specific regulations, and

they employ the same sales and marketing techniques and activities.

Our two reportable segments are United States and Foreign Countries.

Our foreign operations have material revenues and long lived assets in the United Kingdom and Ireland,

(referred to as “Europe” in the following table). Summary information for our reportable segments is as follows:

2007

2006

2005

in thousands

Revenues:
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Foreign Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Foreign Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 721,408

$ 616,436

$ 508,247

149,467
61,892

211,359

128,743
44,458

173,201

69,098
32,112

101,210

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 932,767

$ 789,637

$ 609,457

Income before income taxes:

United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Foreign Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 167,603
23,637

$ 150,820
21,754

$ 102,286
9,694

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 191,240

$ 172,574

$ 111,980

Total assets:

United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Foreign Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,304,248
303,911

$1,016,146
311,760

$ 978,027
69,633

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,608,159

$1,327,906

$1,047,660

Long-lived assets:
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Foreign Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Foreign Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,165,419

$ 895,299

$ 859,497

132,445
100,019

232,464

168,007
45,998

214,005

23,617
20,504

44,121

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,397,883

$1,109,304

$ 903,618

Revenues are attributed to countries based on the location of customers. Intercompany revenues recorded by
the United States for work performed in Canada are eliminated prior to reporting United States revenues. The
same accounting principles and critical accounting policies are used in the preparation of the financial statements
for both reporting segments.

53

Detailed information for our United States reporting segment is as follows:

2007

2006

2005

Regulated medical waste management services . . . . . . . . . . . . . . . . . . . . . . . .
Regulated returns management services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$637,731
83,677

in thousands
$557,927
58,509

$495,469
12,778

Total Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

721,408

616,436

508,247

Net interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-down of investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Debt extinguishment and refinancing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3CI settlement of class action litigation (2005)/ proceeds from insurance

(2006 and 2007) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Licensing legal settlement
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

27,347
—
—

23,406
1,000
—

11,621
—
197

(3,300)
—
167,603
64,562

(1,025)
—
150,820
63,524

36,481
1,823
102,286
41,298

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$103,041

$ 87,296

$ 60,988

Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Capital expenditures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 22,204
37,222

$ 19,893
25,556

$ 16,317
20,011

Detailed information for our Foreign Countries reporting segment is as follows:

2007

2006

2005

Regulated medical waste management services . . . . . . . . . . . . . . . . . . . . . . . .
Property equipment and technology license sales . . . . . . . . . . . . . . . . . . . . . . .

$210,857
502

in thousands
$172,653
548

$100,147
1,063

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

211,359

173,201

101,210

Net interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Write-down of investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Debt extinguishment and refinancing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5,028
2,930
—
23,637
8,300

3,655
—
—
21,754
3,780

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 15,337

$ 17,974

Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Capital expenditures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

8,933
11,175

$

7,143
10,858

626
—
250
9,694
3,528

6,166

5,114
6,303

$

$

Note 18—Accumulated Other Comprehensive Income

The components of total comprehensive income are net income, the change in cumulative currency
translation adjustments and gains and losses on derivative instruments qualifying as cash flow hedges. The
following table sets forth the components of total comprehensive income for 2007, 2006 and 2005:

Currency
translation
adjustments

Unrealized
gains
(losses) on
cash flow
hedges

Total
accumulated
other
comprehensive
income

Ending balance December 31, 2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fiscal 2005 change . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ending balance December 31, 2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fiscal 2006 change . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Ending balance December 31, 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fiscal 2007 change . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ending balance December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 2,464
(1,817)
647
4,350

4,997
25,125
$30,122

$

in thousands
(3)
(98)
(101)
333

232
166
$ 398

$ 2,461
(1,915)
546
4,683

5,229
25,291
$30,520

54

Note 19—Selected Quarterly Financial Data (Unaudited)

The following table summarizes our unaudited consolidated quarterly results of operations as reported for

2007 and 2006:

First
Quarter
2007

Second
Quarter
2007

Third
Quarter
2007

Fourth
Quarter
2007

Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gain on sale of assets . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of intangible assets . . . . . . . . . . . . . . . . . .
Impairment of fixed assets . . . . . . . . . . . . . . . . . . . . . .
Arbitration award and related costs . . . . . . . . . . . . . . .
Write-down of investment . . . . . . . . . . . . . . . . . . . . . .
Insurance proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
* Basic earnings per common share . . . . . . . . . . . . . . .
* Diluted earnings per common share . . . . . . . . . . . . .

$211,049
94,236
823
—
(650)
—
—
500
29,387
0.33
0.32

$
$

in thousands, except per share data
$237,323
106,814
—
—
—
—
—
—
32,895
0.38
0.37

$232,845
104,517
1,075
(228)
(611)
—
—
—
31,998
0.37
0.36

$251,550
112,354
201
(2,041)
—
(13,904)
(2,930)
2,800
24,098
0.27
0.27

$
$

$
$

$
$

First
Quarter
2006

Second
Quarter
2006

Third
Quarter
2006

Fourth
Quarter
2006

Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross profit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment of fixed assets . . . . . . . . . . . . . . . . . . . . . .
Write-down of investment in securities . . . . . . . . . . . .
Insurance proceeds . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net Income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
* Basic earnings per common share . . . . . . . . . . . . . . .
* Diluted earnings per common share . . . . . . . . . . . . .

$179,249
78,753
—
—
—
23,525
0.27
0.26

in thousands, except per share data
$203,267
90,523
—
—
—
27,532
0.31
0.30

$198,424
87,561
(300)
(1,000)
—
25,168
0.28
0.28

$208,697
93,030
—
—
1,025
29,045
0.33
0.32

Year 2007

$932,767
417,921
2,099
(2,269)
(1,261)
(13,904)
(2,930)
3,300
118,378
1.35
1.32

$
$

Year 2006

$789,637
349,867
(300)
(1,000)
1,025
105,270
1.19
1.16

*

EPS calculated on a quarterly basis, and, as such, the amounts may not total the calculated full-year EPS.

55

STERICYCLE, INC. AND SUBSIDIARIES

SCHEDULE II—VALUATION AND ALLOWANCE ACCOUNTS
In thousands

Balance
12/31/04

Charges to
Expenses

Other
Charges(1)

Write-offs/
Payments

Balance
12/31/05

Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . .
Deferred tax valuation allowance . . . . . . . . . . . . . . . . . . . .

$4,188
922

$2,645
—

$1,215
—

$(3,238) $4,810
—

(922)

Balance
12/31/05

Charges
to Expenses

Other
Charges(1)

Write-offs/
Payments

Balance
12/31/06

Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . .

$4,810

$4,194

$

48

$(3,641) $5,411

Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . .

$5,411

$4,392

$ 293

$(3,939) $6,157

(1) Amounts consist primarily of costs assumed from acquired companies recorded prior to the date of

acquisition and currency translation adjustments.

Balance
12/31/06

Charges
to Expenses

Other
Charges(1)

Write-offs/
Payments

Balance
12/31/07

56

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Statement Disclosure

None.

Item 9A. Controls and Procedures

(a) Evaluation of disclosure controls and procedures.

Our management, with the participation of our President and Chief Executive Officer and our Chief
Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of
the end of the fiscal year covered by this Report. On the basis of this evaluation, our President and Chief
Executive Officer and our Chief Financial Officer each concluded that our disclosure controls and procedures
were effective.

The term “disclosure controls and procedures” is defined in Rule 13a-14(e) of the Securities Exchange Act
of 1934 as “controls and other procedures designed to ensure that information required to be disclosed by the
issuer in the reports, files or submits under the Act is recorded, processed, summarized and reported, within the
time periods specified in the [Securities and Exchange] Commission’s rules and forms.” Our disclosure controls
and procedures are designed to ensure that material information relating to us and our consolidated subsidiaries is
accumulated and communicated to our management, including our President and Chief Executive Officer and our
Chief Financial Officer, as appropriate to allow timely decisions regarding our required disclosures.

(b) Internal control over financial reporting.

Management’s Report on Internal Control over Financial Reporting and our Independent Registered Public

Accounting Firm’s Attestation Report are included in Item 8.

(c) Changes in internal controls.

There were no significant changes in our internal controls or in other factors that could materially affect

those controls during the quarter ended December 31, 2007.

Item 9B. Other Information

None.

57

Item 10. Directors and Executive Officers of the Registrant

PART III

The information required by this Item regarding our directors is incorporated by reference to the information
contained under the caption “Election of Directors” in our definitive proxy statement for our 2008 Annual
Meeting of Stockholders to be held on May 29, 2008, to be filed pursuant to Regulation 14A.

The information required by this Item regarding our executive officers is contained under the caption

“Executive Officers of the Registrant” in Part I of this Report.

The information required by this Item regarding compliance with Section 16(a) of the Securities Exchange
Act of 1934 is incorporated by reference to the information contained under the caption “Section 16(a) Beneficial
Ownership Reporting Compliance” in our definitive proxy statement for our 2008 Annual Meeting of
Stockholders to be held on May 29, 2008, to be filed pursuant to Regulation 14A.

We have adopted a code of business conduct that applies generally to all of our employees and, in addition,
we have a adopted a finance department code of ethics that applies specifically to our President and Chief
Executive Office, Chief Financial Officer, Vice President-Finance and the members of our finance department.
Both codes are available on our website, www.stericycle.com, under “About Us/Corporate Overview,” Any
amendment to or waiver of the finance department code of ethics will be posted on our website within five
business days after the date of the amendment or waiver.

Item 11. Executive Compensation

The information required by this Item is incorporated by reference to the information contained under the
caption “Compensation Discussion and Analysis” and following sections (up to Item 2) in our definitive proxy
statement for our 2008 Annual Meeting of Stockholders to be held on May 29, 2008, to be filed pursuant to
Regulation 14A.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters

The information required by this Item is incorporated by reference to the information contained under the
captions “Stock Ownership” and “Compensation Discussion and Analysis” and following sections (up to Item 2)
in our definitive proxy statement for our 2008 Annual Meeting of Stockholders to be held on May 29, 2008 to be
filed pursuant to Regulation 14A.

Item 13. Certain Relationships and Related Transactions

No information is required by this Item.

Item 14. Principal Accountant Fees and Services

Audit Fees:

The aggregate fees billed by our independent public accountants, Ernst & Young LLP, for professional
services rendered in connection with the audit of our annual financial statements and the audit of our internal
controls over financial reporting, and review of our interim financial statements included in our quarterly reports
on Form 10-Q for the fiscal years ended December 31, 2007 and 2006 were approximately $1.2 million and
$1.1 million, respectively.

Audit Related Fees:

In the years ended December 31, 2007 and 2006 Ernst & Young LLP did not bill us for any audit related
fees. Ernst & Young LLP did not perform any other assurance or related services during either of these two fiscal
years.

58

Tax Fees:

Ernst & Young LLP did not provide any tax compliance, tax advice or tax planning services to us during the

fiscal years ended December 31, 2007 and 2006.

All Other Fees:

In 2007 we subscribed to the Ernst & Young online research tool at cost of $2,000.

Ernst & Young LLP did not provide any other services to us during the fiscal years ended December 31,

2007 and 2006.

In accordance with policies adopted by the Audit Committee of our Board of Directors, all audit and
non-audit related services to be performed for us by our independent public accountants must be approved in
advance by the Committee.

59

Item 15. Exhibits and Financial Statement Schedules

(a) List of Financial Statements, Financial Statement Schedule and Exhibits

PART IV

We have filed the following financial statements and financial statement schedule as part of this report:

Report of Independent Registered Public Accounting Firm on Internal Control Over Financial

Reporting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Report of Independent Registered Public Accounting Firm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Financial Statements—Stericycle, Inc. and Subsidiaries

Consolidated Balance Sheets as of December 31, 2007 and 2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Income for Each of the Years in the Three-Year Period Ended

Page

29
30

31

December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32

Consolidated Statements of Cash Flows for Each of the Years in the Three-Year Period Ended

December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Changes in Shareholders’ Equity for Each of the Years in the Three-Year
Period Ended December 31, 2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Schedule II—Valuation and Allowance Accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

33

34
35
56

All other financial statement schedules have been omitted because they are not applicable to us or the

required information is shown in the consolidated financial statements or notes thereto.

60

We have filed the following exhibits with this report:

Exhibit
Index

3.1*

3.2*

3.3*

3.4*

3.5

4.1*

10.1*

Filed with
Electronic
Submission

Description

Amended and restated certificate of incorporation (incorporated by reference to Exhibit
3.1 to our 1996 Form S-1)

First certificate of amendment to amended and restated certificate of incorporation
(incorporated by reference to Exhibit 3.1 to our current report on Form 8-K filed
November 29, 1999)

Second certificate of amendment to amended and restated certificate of incorporation
(incorporated by reference to Exhibit 3.4 to our annual report on Form 10-K for 2002)

Third certificate of amendment to amended and restated certificate of incorporation
(incorporated by reference to Exhibit 3.4 to our registration statement on Form S-4 as
declared effective on October 10, 2007 (Registration No. 333-144613)

Amended and restated bylaws (incorporated by reference to Exhibit 3(ii).1 to our current
report on Form 8-K filed February 22, 2008)

x

Specimen certificate for shares of our common stock, par value $.01 per share
(incorporated by reference to Exhibit 4.1 to our 1996 Form S-1)

Credit Agreement dated as of August 24, 2007 entered into by Stericycle, Inc. and certain
of its subsidiaries as borrowers, Bank of America, N.A., as administrative agent, swing
line lender, a lender and a letter of credit issuer, other lenders party to the Credit
Agreement, JPMorgan Chase Bank, N.A., as syndication agent, and Citibank, N.A., Fortis
Capital Corp. and The Royal Bank of Scotland plc, as co-documentation agents, with
Banc of America Securities LLC and J.P. Morgan Securities Inc., as joint lead arrangers
and joint book managers (incorporated by reference to our current report on Form 8-K
filed August 28, 2007)

10.2*† Directors Stock Option Plan (Amended and Restated) (“Directors Plan”) (incorporated by

reference to Exhibit 4.1 to our registration statement on Form S-8 filed August 2, 2001
(Registration No. 333-66542))

10.3*†

10.4*†

10.5*†

10.6*†

10.7*†

10.8*†

10.9*†

First amendment to Directors Plan (incorporated by reference to Exhibit 10.9 to our
annual report on Form 10-K for 2001)

Form of stock option agreement for option grant under Directors Plan (incorporated by
reference to Exhibit 10.1 to our quarterly report on Form 10-Q for the quarter ended
September 30, 2004)

1997 Stock Option Plan (“1997 Plan”) (incorporated by reference to Exhibit 10.3 to our
annual report on Form 10-K for 1997)

First amendment to 1997 Plan (incorporated by reference to Exhibit 10.9 to our 1999
Form S-3)

Second amendment to 1997 Plan (incorporated by reference to Exhibit 10.12 to our
annual report on Form 10-K for 2001)

Third amendment to 1997 Plan (incorporated by reference to Exhibit 10.16 to our annual
report on Form 10-K for 2003)

2000 Nonstatutory Stock Option Plan (“2000 Plan”) (incorporated by reference to
Exhibit 10.13 to our annual report on Form 10-K for 2001)

61

Exhibit
Index

10.10*†

10.11*†

10.12*†

10.13*†

10.14†

Description

First amendment to 2000 Plan (incorporated by reference to Exhibit 10.14 to our annual
report on Form 10-K for 2001)

Second amendment to 2000 Plan (incorporated by reference to Exhibit 10.15 to our
annual report on Form 10-K for 2001)

Third amendment to 2000 Plan (incorporated by reference to Exhibit 4.2 to our registration
statement on Form S-8 filed December 20, 2002 (Registration No. 333-102097))

2005 Incentive Stock Plan (“2005 Plan”) (incorporated by reference to Exhibit 4.1 to our
registration statement on Form S-8 filed August 9, 2005 (Registration No. 333-127353)

Form of stock option agreement for option grant under 1997 Plan, 2000 Plan and 2005
Plan (incorporated by reference to Exhibit 10.5 to our annual report on Form 10-K for
2005)

10.15†

Bonus conversion program (2008 plan year)

10.16†

Form of stock option agreement for option grant under bonus conversion program

10.17*†

10.18*†

10.19*†

10.20*†

14

21

23

31.1

31.2

32

Employee Stock Purchase Plan (“ESPP”) (incorporated by reference to Exhibit 4.1 to our
registration statement on Form S-8 filed August 2, 2001 (Registration No. 333-66544)

First amendment to ESPP (incorporated by reference to Exhibit 10.21 to our annual
report on Form 10-K for 2002)

Plan of Compensation for Outside Directors (incorporated by reference to Exhibit 10.1 to
our current report on Form 8-K filed August 11, 2006)

First amendment to Plan of Compensation for Outside Directors (incorporated by
reference to Exhibit 10.19 to our annual report on Form 10-K for 2006)

Code of ethics (incorporated by reference to Exhibit 10.14 to our annual report on
Form 10-K for 2003)

Subsidiaries

Consent of Independent Registered Public Accounting Firm

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

Section 1350 Certification of Chief Executive Officer and Chief Financial Officer

Filed with
Electronic
Submission

x

x

x

x

x

x

x

Previously filed

*
† Management contract or compensatory plan required to be filed pursuant to Item 601 of Regulation S-K

References to our “1996 Form S-1” are to our registration statement on Form S-1 as declared effective on
August 22, 1996 (Registration No. 333-05665); and references to our “1999 Form S-3” are to our registration
statement on Form S-3 as declared effective on February 4, 1999 (Registration No. 333-60591).

62

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this

report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 29, 2008

Name

Title

Date

/s/

JACK W. SCHULER
Jack W. Schuler

/s/ MARK C. MILLER

Mark C. Miller

/s/

FRANK J.M. TEN BRINK
Frank J.M. ten Brink

Chairman of the Board of Directors

February 29, 2008

President and Chief Executive

February 29, 2008

Officer and a Director (Principal
Executive Officer)

Executive Vice President and Chief

February 29, 2008

Financial Officer (Principal
Financial and Accounting
Officer)

/s/ ROD F. DAMMEYER

Director

February 29, 2008

Rod F. Dammeyer

/s/ WILLIAM K. HALL

Director

February 29, 2008

February 29, 2008

February 29, 2008

February 29, 2008

February 29, 2008

William K. Hall

/s/

JONATHAN T. LORD, M.D
Jonathan T. Lord, M.D.

/s/

JOHN PATIENCE
John Patience

/s/

THOMAS R. REUSCHÉ
Thomas R. Reusché

/s/

PETER VARDY
Peter Vardy

Director

Director

Director

Director

63

[THIS PAGE INTENTIONALLY LEFT BLANK]

[THIS PAGE INTENTIONALLY LEFT BLANK]

[THIS PAGE INTENTIONALLY LEFT BLANK]

2 0 0 7

C O R P O R A T E

I N F O R M A T I O N

O f f i c e r s

Mark C. Miller

President, Chief Executive Officer and Director

Richard Kogler

Executive Vice President, Chief Operating Officer

Frank J.M. ten Brink

Executive Vice President, Chief Financial Officer

Richard L. Foss

Executive Vice President, Corporate Development

Shan S. Sacranie

Executive Vice President, International

Michael Collins

President, Return Management Services

B o a r d o f D i r e c t o r s

Jack W. Schuler • Chairman of the Board

Chairman, Nominating and Governance Committee
Member, Audit Committee

Mark C. Miller • President & Chief Executive Officer

William K. Hall

Co-Founder & Chairman • Procyon Technologies, Inc.
Member, Compensation Committee

John Patience

Co-Founder & Partner • Crabtree Partners
Member, Nominating and Governance Committee
Member, Audit Committee

Peter Vardy

Managing Partner • Peter Vardy & Associates (Ret.)
Member, Compensation Committee

Rod F. Dammeyer

President • CAC, LLC
Chairman, Audit Committee
Member, Nominating and Governance Committee

Thomas R. Reusché

Retired Co-Founder • Madison Dearborn Partners, Inc.
Member, Audit Committee

Jonathan T. Lord, M.D.

Senior Vice President and Chief Innovation Officer
Humana, Inc.
Chairman, Compensation Committee
Member, Nominating and Governance Committee

I n d e p e n d e n t A u d i t o r s

Ernst & Young LLP
Sears Tower
233 S. Wacker Drive
Chicago, Illinois 60606

L e g a l C o u n s e l

Johnson and Colmar
300 S. Wacker Drive, Suite 1000
Chicago, Illinois 60606

T r a n s f e r A g e n t

LaSalle Bank N.A.
135 S. LaSalle Street, Suite 1946
Chicago, Illinois 60603

F o r m 1 0 - K

Additional copies of this Annual Report or Form 10-K filed
with the Securities and Exchange Commission are available,
without charge, upon request from the company,
Investor@stericycle.com or (800) 643-0240 ext. 2012.

A n n u a l M e e t i n g

The annual meeting of stockholders will be held
on Thursday, May 29, 2008 at 11:00 AM at

Embassy Suites Hotel – O’Hare
5500 N. River Road
Rosemont, Illinois 60018

N a s d a q ® S y m b o l

SRCL

28161 N. Keith Drive
Lake Forest, IL 60045

(800) 643-0240

www.stericycle.com